Novel Lactobacillus plantarum strains, polysaccharides derived from these strains, and their applications
By identifying and characterizing a novel *Lactobacillus plantarum* strain IMB19 and its capsular polysaccharide CPS-100, CD8+ T cells were activated and differentiated into M1 phenotype macrophages, thus solving the problem of tumor immune evasion and achieving effective tumor suppression.
Patent Information
- Application Number
- CN202610316528.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-10
- Filing Date
- 2021-01-11
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, tumor cells grow and proliferate through immune evasion mechanisms, there is a lack of effective tumor immunotherapy, and the regulatory mechanism of probiotics on the immune system is unclear, resulting in poor treatment effects.
A novel *Lactobacillus plantarum* strain IMB19 with immunostimulatory activity and its capsular polysaccharide CPS-100 were identified and characterized. This strain enhances the host immune response to inhibit tumor growth by activating CD8+ T cells and differentiating M1 phenotype macrophages.
It significantly increases the number of effector T cells, inhibits Treg production, enhances the stimulation and inhibition of the immune system against tumors, and effectively inhibits tumor growth and proliferation.
Smart Images

Figure CN123106934A_ABST
Abstract
Description
[0001] This invention application is a divisional application of the invention patent application filed on January 11, 2021, with application number 202180014140.2 (international application number PCT / KR2021 / 000351) entitled "Novel Lactobacillus plantarum strain, polysaccharide derived from the strain and its uses". Technical Field
[0002] This invention relates to a novel Lactobacillus plantarum strain IMB19, polysaccharides derived from said strain, and their uses, and more particularly to a Lactobacillus plantarum strain IMB19 with accession number KCTC 14337BP that has immunostimulatory and antitumor activities, polysaccharides derived from said strain, and their uses for immunomodulation, tumor suppression, and treatment of infectious diseases. Background Technology
[0003] Mammals possess a microbial community that constantly interacts with the immune system. Symbiotic microbes enter into a symbiotic relationship with the host and interact with the host in various processes, such as digestion, behavior, and maturation of the immune system (Cerf-Bensussan N., Gaboriau-Routhiau V. The immune system and the gutmicrobiota: friends or foes? Nat. Rev. Immunol. 2010;10(10):735-44.). Similarly, fungi are present in the human body and influence the host's immune system (Wheeler ML, Limon JJ, Underhill DMImmunity to Commensal Fungi: Detente and Disease. Annu. Rev. Pathol. 2017;12:359-85.). Innate immune cells detect various pathogen-associated molecular patterns (PAMPs), including polysaccharides, on the surface of fungal cells via pattern recognition receptors (PRRs) such as toll-like receptors (TLRs). Upon detecting a signal, innate immune cells produce immune signaling molecules (such as cytokines) to alter gene expression profiles and control acquired immunity (Iliev ID, Leonardi I. Nat. Rev. Immunol. 2017;17(10):635-46.; Underhill DM, Iliev I.D., Nat. Rev. Immunol. 2014;14(6):405-16.; and Brubaker SW, Bonham KS, Zaoni I. et al. Annu. Rev. Immunol. 2015;33:257-90.).
[0004] The WHO defines probiotics as live microorganisms that, when administered in appropriate amounts, are beneficial to the health of the host (Nat. Rev. Gastroenterol Hepatol 11, 506-514 (2014)). Probiotics act as supplements to the host's gut microbiota and have been reported to be effective in improving intestinal barrier function and modulating the host's immune system (Microb. Ecol. Health Dis. 26, 25877 (2015)). Most probiotics belong to the phylum Firmicutes (the largest single phylum of bacteria), and most are Gram-positive bacteria with low "G+C" content, primarily classified in the genera *Bacillus* and *Clostridium*. *Lactobacillus* species are lactic acid bacteria (LAB) belonging to the family *Lactobacillaceae*. *Lactobacillus* is a well-known group of microorganisms with varying ecological states. Several types of LAB are known to be traditionally associated with foods such as milk, dairy products, fermented foods, and sausages. Lactobacillus is a group of microorganisms recognized by the FDA as GRAS (Generally Recognized As Safe) and widely used in the food and other industries. Lactobacillus is classified as a conditionally anaerobic, non-spore-forming, inactive, rod-shaped, and Gram-positive bacterium, and is generally considered catalase-negative. Lactobacillus can exhibit homofermentation or heterofermentation characteristics and produces lactic acid as the end product of primary fermentation (Front Cell Infect Microbiol. 2, 86 (2012)). Lactobacillus forms smooth, raised colonies.
[0005] Due to the similar biochemical and morphological characteristics of lactic acid bacteria (LABs), molecular identification methods are needed to identify individual strains. Several types of lactic acid bacteria have been isolated and characterized from foods, particularly fermented foods. Fermentation generally refers to biochemical changes caused by microorganisms. Kimchi (a traditional Korean food) is primarily fermented cabbage and has beneficial nutritional and health benefits (Crit. Rev. Food Sci. Nutr. 34, 175-203 (1994)). Kimchi is known to contain a unique microbial community. According to some reports, lactic acid bacteria are known to be predominantly found in kimchi, with *Weissella*, *Lactobacillus*, and *Leuconostoc* being the dominant species, and *Lactobacillus plantarum* is considered the most dominant strain (Food Sci. Biotechnol. 19, 641-646 (2010)). *Lactobacillus plantarum* is one of the most studied strains due to its strain-specific probiotic spectrum and its technological applications in the food industry. Most kimchi microorganisms can be cultured (Int. J. Food Microbiol. 102, 143-150 (2005)), and the isolation of individual microorganisms is essential for studying their health benefits.
[0006] Meanwhile, cancer growth and proliferation are strictly regulated by the host's immune response. For tumor cells to grow and proliferate, they must evade the surveillance of the immune system, which induces early tumor cell death. Tumor cells evade the immune system by creating an immunosuppressive tumor microenvironment through various pathways, such as cytokine secretion and molecular expression on the cell surface, thereby growing and proliferating. Various efforts have been made to induce or enhance the immune system as cancer treatment strategies targeting this immune evasion mechanism. Tumor immunotherapy is described as a treatment method used to restore or enhance the immune system's ability to recognize or destroy tumors, thereby overcoming the immunosuppression or evasion mechanisms acquired through tumors. In 2011, the immunotherapy drug ipilimumab was successfully used to treat patients with malignant melanoma. Since then, various immunotherapeutic agents, such as nivolumab and pembrolizumab, have been continuously developed.
[0007] As a tool for tumor immunotherapy, there are increasing reports and case studies on the importance and application of the gut microbiota. The gut microbiota plays a crucial role in shaping the host's local and systemic immune responses (Science 330, 1768-1773 (2010), Cell 148, 1258-1270 (2012)). The diversity and composition of the gut microbiota have also been shown to influence responsiveness to chemotherapy (Cancer Immunol. Immunother. 55, 1470-1479 (2006); Science 342, 971-976 (2013)). In particular, certain symbiotic microorganisms have been found to be associated with the activation of spontaneous antitumor immunity, and have been shown to exhibit synergistic effects on the therapeutic efficacy of immunotherapeutic agents in experiments (Science 350, 1084-1089 (2015); Science 350, 1079-1084 (2015)) and in human cancer (Science 359, 91-97 (2018); Nature 453, 620-625 (2008)). Therefore, it is increasingly clear that certain strains (such as the gut microbiota) can also influence the progression of extramucosal and distant tumors. Based on these various reports, alterations to the gut microbiota are considered an effective and feasible clinical treatment option. Recent studies have demonstrated the synergistic effects of specific strains or strain communities on the host immune system or antitumor immunity from the perspective of probiotics; however, information on the mechanisms (such as the active ingredients derived from specific strains and their signaling pathways that demonstrate these effects) is scarce.
[0008] In particular, as considerations for treating patients with such microorganisms or their metabolites, some patients must suppress an overactive immune response (i.e., allergic reactions or autoimmune diseases), while others must enhance their immune system (i.e., cancer or viral infections). For example, when Bifidobacterium, a Th17-induced probiotic, was administered to animal models of rheumatoid arthritis, arthritis symptoms worsened (Tze Guan Tan, 113(50):E8141-E8150, 2016). Therefore, identifying beneficial microorganisms and elucidating the mechanisms of their action factors is crucial for treatment.
[0009] To address this technical background, the inventors have made significant efforts to elucidate the clear correlation and mechanism between the composition, structure, molecular weight, and immunomodulatory activity of microbial polysaccharides. A novel *Lactobacillus plantarum* strain with significantly high immunomodulatory activity was identified from kimchi (a traditional Korean food) and deposited at the Korean Center for Biological Resources under accession number KCTC 14337BP. Furthermore, it has been demonstrated that when the host is fed the novel *Lactobacillus plantarum* strain KCTC 14337BP, the number of effector T cells significantly increases and Treg production is suppressed, thereby stimulating the host's immune system and inhibiting tumor growth and proliferation.
[0010] Furthermore, the inventors not only identified and characterized the novel strain, but also determined that the capsular polysaccharide of the novel strain and its fraction with a specific structure (CPS-100) are effective molecules exhibiting immunostimulatory and enhancing effects. They also determined that stimulating antitumor immune responses through various mechanisms (such as activation of CD8+ T cell function, increased macrophage infiltration in tumors induced by CPS, and macrophage differentiation / reprogramming into an inflammatory phenotype) can significantly inhibit tumor growth, thus completing the present invention.
[0011] The information described in the background section is only intended to improve the understanding of the background of the present invention, and should not be construed as including information that forms related techniques known to those skilled in the art to which this invention pertains. Summary of the Invention
[0012] The purpose of this invention is to provide a novel strain with immunostimulatory activity.
[0013] Another object of the present invention is to provide a polysaccharide derived from the strain having immunostimulatory activity.
[0014] Another object of the present invention is to provide the use of the strain and the polysaccharides derived from the strain for immunomodulation and / or prevention, improvement or treatment of tumors or infectious diseases.
[0015] To achieve the above objectives, the present invention provides a strain of Lactobacillus plantarum IMB19 with accession number KCTC 14337BP.
[0016] Furthermore, the present invention provides a capsular polysaccharide derived from the strain that has immunomodulatory activity.
[0017] Furthermore, the present invention provides a method for producing capsular polysaccharides with immune-enhancing activity, comprising culturing the strain and obtaining capsular polysaccharides from the cultured strain.
[0018] Furthermore, the present invention provides a polysaccharide represented by the following formula I:
[0019] [Formula I]
[0020] -[-DBIFGCEHA-] n -
[0021] In equation I,
[0022] A and D are galactose.
[0023] B, C, E, G, and H are rhamnose.
[0024] F is N-acetylglucosamine.
[0025] I is glucose, and
[0026] n is an integer from 1 to 10.
[0027] Furthermore, the present invention provides a composition for immunomodulation containing the strain and / or the polysaccharide as active ingredients.
[0028] Furthermore, the present invention provides a pharmaceutical composition for the prevention or treatment of tumors or infectious diseases, which contains the strain and / or the polysaccharide as active ingredients.
[0029] Furthermore, the present invention provides a food composition for immune enhancement, which contains the strain and / or the polysaccharide as active ingredients.
[0030] Furthermore, the present invention provides a method for preventing, improving, or treating tumors or infectious diseases, comprising administering the strain and / or the polysaccharide to a subject.
[0031] Furthermore, the present invention provides the use of the strain and / or the polysaccharide for immunomodulation and / or prevention, improvement or treatment of tumors or infectious diseases.
[0032] Furthermore, the present invention provides the use of the strain and / or the polysaccharide for the manufacture of compositions for immunomodulation.
[0033] Furthermore, the present invention provides the use of the strain and / or the polysaccharide for the manufacture of pharmaceutical compositions for the prevention or treatment of tumors or infectious diseases.
[0034] Furthermore, the present invention provides the use of the strain and / or the polysaccharide in the manufacture of food compositions for immune enhancement.
[0035] Furthermore, the present invention provides a method for generating inflammatory T cells, comprising initiating antigen-presenting cells with Lactobacillus plantarum strain IMB19 and / or a polysaccharide having formula I, and co-culturing the initiated antigen-presenting cells with T cells.
[0036] Furthermore, the present invention provides a method for generating M1 phenotype macrophages, comprising differentiating macrophages into M1 phenotype macrophages by treating macrophages with Lactobacillus plantarum IMB19 strain and / or a polysaccharide having formula I, and obtaining the differentiated M1 phenotype macrophages.
[0037] Furthermore, the present invention provides a cell therapy agent for the prevention or treatment of tumors or infectious diseases, which contains inflammatory T cells and / or M1 phenotype macrophages generated by the above method as active ingredients.
[0038] Specifically, the present invention includes, but is not limited to, the following:
[0039] 1. A strain of Lactobacillus plantarum IMB19, with accession number KCTC 14337BP.
[0040] 2. A capsular polysaccharide derived from the strain described in item 1, which has immunomodulatory activity.
[0041] 3. A polysaccharide represented by the following formula I:
[0042] [Formula I]
[0043] -[-DBIFGCEHA-] n -
[0044] In equation I,
[0045] A and D are galactose.
[0046] B, C, E, G, and H are rhamnose.
[0047] F is N-acetylglucosamine.
[0048] I is glucose, and
[0049] n is an integer of 1 or greater.
[0050] 4. The polysaccharide according to item 3, wherein the galactose of at least one of A and D is phosphorylated.
[0051] 5. The polysaccharide according to item 4, wherein the hydroxyl group (-OH) at the 1-position of A is phosphorylated.
[0052] 6. The polysaccharide according to item 4, wherein the hydroxyl group (-OH) at the 6-position of D is phosphorylated.
[0053] 7. The polysaccharide according to item 3, wherein n is 2 or greater, and the repeating units A and D are linked by phosphodiester linkage.
[0054] 8. The polysaccharide according to item 3, wherein in formula I,
[0055] D and B are linked by an α-1,3-glycoside, and B and I are linked by an α-1,3-glycoside.
[0056] I and F are linked via a β-1,6-glycoside linkage.
[0057] F and G are linked via α-1,2-glycoside linkage, G and C are linked via α-1,2-glycoside linkage, C and E are linked via α-1,2-glycoside linkage, and E and H are linked via α-1,2-glycoside linkage.
[0058] H and A are linked via an α-1,6-glycoside linkage.
[0059] 9. The polysaccharide according to item 3, having the structure of formula II:
[0060] [Formula II]
[0061]
[0062] n is an integer of 1 or greater.
[0063] 10. A method for producing the polysaccharide according to claim 3, comprising:
[0064] (a) Cultivating the strain described in item 1; and
[0065] (b) Obtain capsular polysaccharides from the cultured strain.
[0066] 11. A composition for immunomodulation comprising the strain according to claim 1 or the polysaccharide according to any one of claims 3 to 9 as an active ingredient.
[0067] 12. The composition according to item 11, wherein the immune modulation is immune enhancement.
[0068] 13. A pharmaceutical composition for the prevention or treatment of tumors or infectious diseases, comprising the strain according to claim 1 or the polysaccharide according to any one of claims 3 to 9 as an active ingredient.
[0069] 14. The pharmaceutical composition according to claim 13, wherein the tumor is selected from melanoma, breast cancer, kidney cancer, lung cancer, bladder cancer, and rectal cancer.
[0070] 15. A method of treating a tumor or infectious disease, comprising administering the strain according to claim 1 or the polysaccharide according to any one of claims 3 to 9 to a subject.
[0071] 16. Use of a strain according to claim 1 or a polysaccharide according to any one of claims 3 to 9 for the prevention or treatment of tumors or infectious diseases.
[0072] 17. Use of a strain according to claim 1 or a polysaccharide according to any one of claims 3 to 9 for the manufacture of a pharmaceutical composition for the prevention or treatment of infectious diseases.
[0073] 18. A food composition for immune enhancement, comprising the strain according to claim 1 or the polysaccharide according to any one of claims 3 to 9 as an active ingredient.
[0074] 19. A method for generating inflammatory T cells, comprising:
[0075] (a) Initiating antigen-presenting cells with the strain described in claim 1 or the polysaccharide according to any one of claims 3 to 9; and
[0076] (b) Co-culture the antigen-presenting cells induced by the above with T cells.
[0077] 20. The method according to claim 19, wherein the antigen-presenting cell is selected from macrophages, B cells, dendritic cells (DCs), and Langerhans cells.
[0078] 21. The method according to item 19, wherein the inflammatory T cell is a cytotoxic T cell or a helper T cell.
[0079] 22. A cell therapy agent for the prevention or treatment of tumors or infectious diseases, comprising inflammatory T cells generated by the method according to claim 19 as an active ingredient.
[0080] 23. A method for generating M1 phenotype macrophages, comprising:
[0081] Macrophages are differentiated into M1 phenotype macrophages by treating macrophages with the strain described in claim 1 or the polysaccharide described in any one of claims 3 to 9; and
[0082] The differentiated M1 phenotype macrophages were obtained.
[0083] 24. The method according to item 23, wherein the expression of at least one selected from MHC I, MHC II, CD68, iNOS2 and CD40 is upregulated in the M1 phenotype macrophages.
[0084] 25. A cell therapy agent for the prevention or treatment of tumors or infectious diseases, comprising M1 phenotype macrophages generated by the method according to claim 23 as an active ingredient. Attached Figure Description
[0085] Figure 1 The levels of inflammatory or anti-inflammatory cytokines in spleen cells after treatment with a strain derived from kimchi are shown.
[0086] The stepwise dilutions for preparing the kimchi suspension were streaked on MRS agar plates and incubated at 37°C for 48 hours. Strains were then obtained from 14 colonies and further incubated in MRS broth for 24 hours. Spleen cells were mixed with each strain at a 1:10 ratio and incubated at 37°C and 5% CO2 for 48 hours. Spleen cell activation was evaluated by measuring cytokine levels in the culture supernatant via ELISA. Data are presented as mean ± SEM values (n=2). Statistical significance for the simulants was calculated using one-way ANOVA: *p < 0.5, **p < 0.01, *p < 0.001.
[0087] Figure 2 The microbiological and biological characteristics of Lactobacillus plantarum strain IMB19 are shown.
[0088] Figure 2 In small figure A, a TEM image of Lactobacillus plantarum strain IMB19 is shown, with the arrow indicating the capsule layer surrounding the cell wall.
[0089] Figure 2 Inset B shows the hemolytic activity of *Lactobacillus plantarum* strain IMB19 after 48 hours of incubation in 5% sheep blood agar. The positive control is *Bacillus cereus* ATCC 27348.
[0090] Figure 2 Figure C shows the gelatin hydrolysis test of Lactobacillus plantarum strain IMB19, with Bacillus cereus ATCC11778 as the positive control.
[0091] Figure 3 The following is a phylogenetic tree diagram of Lactobacillus plantarum IMB19.
[0092] A phylogenetic tree was constructed based on the differences between Lactobacillus plantarum strains, and the OrthANI algorithm was used to calculate the average nucleotide index (ANI), with the distance being proportional to the differences in the genome.
[0093] Figure 4 The results demonstrate the effectiveness of using multiple Lactobacillus plantarum strains to generate Th 17 cells.
[0094] The presentation included flow cytometry data demonstrating the effects of *Lactobacillus plantarum* IMB19, *Lactobacillus plantarum* 3105, *Lactobacillus plantarum* 3106, and *Lactobacillus plantarum* 3107 on naive CD4+ T cells. Dendritic cells induced by *Lactobacillus plantarum* IMB19 were co-cultured with naive CD4+ T cells, anti-CD3 (10 ng / ml), and IL-2 (100 / ml).
[0095] Figure 4 The small figure A i shows a FACS map depicting Th17 cells, where the cells are gated with live CD4+ RORγ+ T cells.
[0096] Figure 4 Small figure A ii shows a bar chart depicting the average number of Th17 cells gated by live CD4+ RORγ+ T cells.
[0097] Figure 4 Small figure B shows Th1 cells gated by live CD4+ T-Bet+ T cells.
[0098] Figure 4 Small figure C shows Th2 cells gated by live CD4+ GATA3+ T cells.
[0099] Figure 4 Small figure D shows Tregs gated by live CD4+ Foxp3+ regulatory T cells.
[0100] Data are presented as mean ± SD, and statistical significance for the simulated data was calculated using one-way ANOVA, ** P < 0.01;
[0101] Figure 5 This demonstrates the ability of *Lactobacillus plantarum* IMB19 to inhibit Treg cells and induce Th17 cells.
[0102] Figure 5 The small figure A i shows representative FACS plots and bar graphs illustrating the effects of *Lactobacillus plantarum* IMB19 on Th17 cells, in which dendritic cells induced by *Lactobacillus plantarum* IMB19 were co-cultured with naive CD4+ T cells, anti-CD3 (0.1 μg / ml), TGF-β (0.5 ng / ml), IL-6 (2 ng / ml), IL1-β (2 ng / ml), IL-2 (100 U / ml), anti-IL4 (10 μg / ml), and anti-IFNγ (10 μg / ml). These cells were gated using live CD4+ RORγ+ T cells.
[0103] Figure 5Small figure Aii shows a representative FACS plot and bar chart, which illustrates the level of interleukin-17 produced by *Lactobacillus plantarum* IMB19 in Th17 cells gated with live CD4+ RORγ+ IL-17+ T cells.
[0104] Figure 5 Figure B shows a representative FACS plot and bar chart, illustrating the inhibitory effect of *Lactobacillus plantarum* IMB19 on Treg cells in vitro. Dendritic cells induced by *Lactobacillus plantarum* IMB19 were co-cultured with naive CD4+ T cells, anti-CD3 (0.1 μg / ml), IL-2 (100 U / ml), and different concentrations of TGF-β. Data are presented as mean ± SEM, and statistical significance was analyzed by general one-way ANOVA. ** p < 0.01, *** p < 0.001;
[0105] Figure 6 This demonstrates an anti-tumor immune response achieved through CD8+ T cell activation enhanced by Lactobacillus plantarum IMB19.
[0106] Figure 6 Inset A shows the results of ELISA analysis of cytokine levels in the supernatant of spleen cell-bacterial co-culture.
[0107] Figure 6 Inset Figure B shows the quantitative results of IFNγ+ CD8+ T cells from a co-culture of spleen CD11c+ dendritic cells and naive CD8+ T cells induced by Lactobacillus plantarum IMB19 or Lactobacillus murineis.
[0108] Figure 6 Inset Figure C shows the quantitative results of IFNγ+ CD8+ T cells from a co-culture of CD11b+ F4 / 80+ peritoneal macrophages and naive CD8+ T cells induced by Lactobacillus plantarum IMB19.
[0109] Figure 6 Inset D shows the quantitative results of Foxp3+ CD4+ T cells from a co-culture of spleen CD11c+ dendritic cells, naive CD4+ T cells, and 2 ng / ml TGF-β induced by Lactobacillus plantarum IMB19.
[0110] Data are presented as mean ± SEM values. B was analyzed using a standard one-way ANOVA and Tukey multiple comparisons. **p < 0.01, ****p < 0.0001.
[0111] Figure 6Figure E schematically illustrates the in vivo cytotoxicity assay of Listeria monocytogenes (LM-OVA) expressed with OVA.
[0112] Figure 6 Inset F illustrates CD8+ T cell-specific cytotoxicity against OVA+ spleen cells mediated by *Lactobacillus plantarum* IMB19 in LM-OVA-infected mice.
[0113] Figure 6 Small figure G schematically illustrates an in vivo B16.F10 melanoma mouse model.
[0114] Figure 6 Inset H illustrates the growth kinetics of B16.F10 melanoma in C57 / BI6 germ-free mice treated with or without *Lactobacillus plantarum* IMB19 or *Lactobacillus murineis*.
[0115] Figure 6 Figure I shows the growth kinetics of B16.F10 melanoma in C57 / BI6 SPF mice treated with or without Lactobacillus plantarum IMB19 or Lactobacillus murineis.
[0116] The data is the mean ± SEM value. Figure 6 F shows the results of the nonparametric two-tailed t-test, and Figure 6 H and Figure 6 I shows the results of two-way ANOVA and Dunnett's multiple comparisons, ** P < 0.01, *** P < 0.001, **** P < 0.0001;
[0117] Figure 7 The dose-dependent effects of Lactobacillus plantarum IMB19 on CD8+ T cells were demonstrated.
[0118] Figure 7 small picture A and Figure 7 Figure B shows the quantitative results of IFNγ+ CD8+ T cells in co-cultures of spleen (7A) or mLN (7B) CD11c+ dendritic cells and naive CD8+ T cells induced by Lactobacillus plantarum IMB19 at different ratios.
[0119] Figure 7Inset Figure C shows the quantitative results of IFNγ+CD8+ T cells in co-cultures of spleen CD11c+ dendritic cells induced by Lactobacillus plantarum IMB19 at different ratios and CD8+ T cells inoculated with naive pmel TCRs in the presence of 100 ng / ml gp-100. Data are presented as mean ± SEM and analyzed by typical one-way ANOVA and Tukey multiple comparisons. ** p < 0.01, *** p < 0.001, **** p < 0.0001;
[0120] Figure 8 This study demonstrates the inhibition of regulatory T cell growth through interleukin-6 production by *Lactobacillus plantarum* IMB19.
[0121] Figure 8 Figure A shows the quantitative results of Foxp3+ CD4+ T cells in co-cultures of spleen CD11c+ dendritic cells and naive CD4+ T cells induced by Lactobacillus plantarum IMB19 at different TGF-β concentrations.
[0122] Figure 8 Inset Figure B shows the quantification of cytokines in a co-culture of spleen CD11c+ dendritic cells and naive CD4+ T cells induced by *Lactobacillus plantarum* IMB19 at a TGF-β concentration of 2 ng / ml, the cells being gated with total CD4+ T cells.
[0123] Figure 8 Figure C shows the quantitative results of Foxp3+ CD4+ T cells in IL-6- / - spleen DCs and in a co-culture of spleen CD11c+ dendritic cells and naive CD4+ T cells induced by Lactobacillus plantarum IMB19 at a TGFβ concentration of 0.01 ng / ml.
[0124] Data are presented as mean ± SEM and analyzed using typical one-way ANOVA and Tukey multiple comparison analysis. *** p < 0.001, ns: not significant;
[0125] Figure 9 This study demonstrated the role of *Lactobacillus plantarum* IMB19 in tumor immunity, while microbial diversity remained unchanged.
[0126] Figure 9 Small figure A shows in Figure 6 The results of phylogenetic analysis of phyla in fecal samples of tumor-bearing mice fed with Lactobacillus plantarum IMB19 in small figure H (%).
[0127] Figure 9 small picture B and Figure 9 Small figure C shows in Figure 6The results of principal coordinate analysis of α diversity (B) and bacterial β diversity in fecal samples from tumor-bearing mice fed with Lactobacillus plantarum IMB19 are shown in small figure H. The data indicate values from two independent experiments.
[0128] Figure 10 The image shown is a transmission electron microscope (TEM) image of Lactobacillus plantarum IMB19.
[0129] Figure 10 Small figure a shows the Lactobacillus plantarum IMB19 bacterial community, with arrows indicating individual bacteria.
[0130] Figure 10 Small figure b shows Lactobacillus plantarum IMB19, with the arrow indicating the thick capsule layer around the cell wall;
[0131] Figure 11 The GC-MS spectra of CPS-derived acetylated methyl glycosides extracted from Lactobacillus plantarum IMB19 are shown, with the sample dephosphorylated without HF treatment (a) or by HF treatment (b), and "i" indicating impurities;
[0132] Figure 12 The GC-MS spectra of acetylated 2-(-)-octyl derivatives (a), rhamnose (b), glucose (c), and galactose acetylated 2-(-)-octyl glycoside standards (d) extracted from Lactobacillus plantarum IMB19 are shown, with "i" indicating impurities;
[0133] Figure 13 The proton spectra (600 MHz, 298 K) of fractions obtained by purification of crude CPS via ion exchange chromatography are shown: CPS (a), CPS-10 (b), CPS-100 (c), CPS-200 (d), CPS-400 (e), CPS-700 (f), and CPS7-1000 (g), with the numbers in parentheses indicating the yield (mg / mg) of each fraction compared to 28 mg of crude CPS.
[0134] Figure 14 Expanded HSQC spectra (600 MHz, 310 K) of the capsular polysaccharide record for *Lactobacillus plantarum* IMB19 are shown: (a) expansion of the anodic region, (b) expansion of the methanol region, with gray density corresponding to the "CH2" carbon, and "*" indicating small anodic signals of repeating unit sugars linked to reduced galactose (Galα and Galβ). For the structure of the repeating unit, refer to... Figure 20 And for the markings, refer to Table 3;
[0135] Figure 15The GC-MS spectrum of acetylated methyl glycosides of CPS-400 extracted from Lactobacillus plantarum IMB19 is shown after the sample was dephosphorylated by HF treatment. "i" indicates impurities and MurA indicates muramic acid, which is a component of bacterial peptidoglycan.
[0136] Figure 16 Extended TOCSU (black) and COZY (cyan / red) spectra (600 MHz, 310 K) records for the capsular polysaccharide CPS-100 of *Lactobacillus plantarum* IMB19 are shown. For the structure of the repeating unit, refer to [reference needed]. Figure 20 And for the markings, refer to Table 3;
[0137] Figure 17 Extended NOESY (black) and COZY (cyan / red) spectra of the capsular polysaccharide CPS-100 of *Lactobacillus plantarum* IMB19 are shown (600 MHz, 310 K). For the structure of the repeating unit, refer to [reference needed]. Figure 20 And for the markings, refer to Table 3;
[0138] Figure 18 Extended HSQC-TOCSY (a) and HMBC (b) NMR spectra (600 MHz, 310 K) records for capsular polysaccharides of *Lactobacillus plantarum* IMB19 are shown. For the structure of repeating units, refer to [reference missing]. Figure 20 And for the markings, refer to Table 3;
[0139] Figure 19 The extended (600 MHz, 310 K) NESY (black) and COZY (cyan / red) spectra of the H-2 proton region of residue BG, which is part of the capsular polysaccharide CPS-100 of *Lactobacillus plantarum* IMB19, are shown. For the structure of the repeating unit, refer to [reference needed]. Figure 20 And for the markings, refer to Table 3;
[0140] Figure 20 The structure of a repeating unit of the capsular polysaccharide CPS-100 from Lactobacillus plantarum IMB19 is shown, where the number 4 indicates the calculated average degree of polymerization, and the phosphate group (P) replacing the oxygen of the 6' carbon residue of D with the 1' carbon of A indicates the phosphodiester linkage between A and D between the repeating units of the polysaccharide.
[0141] Figure 21 HPSEC spectra of individually injected solvents (a), CPS-100 (b), and CPS-400 (c) are shown. As seen in the spectrum of individually injected solvent (a), the peaks at 13.6 min and 14.74 min are solvent-induced artifacts.
[0142] Figure 22 The NMR spectra (600 MHz, 310 K) for the CPS-400 record are shown: (a) superposition of HSQC-TOCSY (black) and HSQC (cyan), (b) superposition of HMBC (black) and HSQC (cyan), (c) HSQC, (d) HSQC-TOCSY, and (e) to (h) TOCSY spectra in different regions. "*" indicates the density of unidentified small motifs, and the markings and delineations of structural units are shown in Table 4.
[0143] Figure 23 Extended HSQC-TOCSY (black / grey) and HSQC (cyan / red) representations of the density of ribitol G are shown, with the HSQC-TOCSY correlations from G1 and G5 indicated by gray dashed lines, and the depiction of markers and structural units is shown in Table 4 (600 MHz, 310 K).
[0144] Figure 24 Results confirming cytokine levels were shown to demonstrate the immunostimulatory activity of capsular polysaccharides in the purified fractions, wherein spleen cells were cultured in the presence of medium (control), CPS fractions (CPS-400 and CPS-100, 50 μg / mL), total CPS (50 μg / mL), and lipopolysaccharide (LPS from E. coli O111:B4, 0.1 μg / mL). Figure 24 As shown, and cell culture supernatant was analyzed by ELISA to evaluate cytokine production, CPS-100 dose-response curves for the production of (a) IFNγ, (b) IL-10, (c) TNF-α, (d) IL-6, (e) IL-12 and (f) IFNγ, where in (f), EC50 (half-maximum effective concentration) was calculated to be 3.16 μM. Data are values from two to three independent experiments with similar results. All bars indicate mean ± SD, * p < 0.05, **** p < 0.0001 (one-way ANOVA with post-hoc Dunnett multiple comparison test), and ND, not detected;
[0145] Figure 25 The study demonstrated that *Lactobacillus plantarum* IMB 19 and CPS inhibit tumor growth by activating CD8+ T cells and improving intratumoral infiltration.
[0146] Figure 25 Inset A shows the growth kinetics of B16.F10 melanoma in C57 / Bi6 SPF mice treated with or without Lactobacillus plantarum IMB 19 or CPS.
[0147] Figure 25 Small figure B shows an image of a tumor isolated from a mouse.
[0148] Figure 25 small picture C and Figure 25 Inset D shows the proportions of tumor-infiltrating CD8+ and CD4+ T cells, as determined by flow cytometry, 16 to 18 days after initiation of treatment with *Lactobacillus plantarum* IMB 19 (C) or CPS (D).
[0149] The data are mean ± SEM values. Data were analyzed using Dunnett's multiple comparisons (A) or a nonparametric two-tailed t-test (CD) in a two-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001.
[0150] Figure 25 small picture E and Figure 25 The small figure F shows the percentage of tumor-infiltrating IFNγ+ CD8+ T cells and the mean fluorescence intensity (MFI) of tumor-infiltrating CD8+ T cells when treated with or without Lactobacillus plantarum IMB 19 (E) or CPS (F). Figure 25 small image G and Figure 25 The small plot H shows the frequency of IFNγ+ CD4+ T cells when treated with or without Lactobacillus plantarum IMB 19(G) or CPS(H), where data are mean ± SEM values and data were analyzed by nonparametric two-tailed t-test, * P < 0.05, ns: not significant;
[0151] Figure 26 The results showed that *Lactobacillus plantarum* IMB19 and CPS did not alter the regulatory T cell population in tumors.
[0152] Figure 26 small picture A and Figure 26 Inset B shows the percentage of tumor-infiltrating CD4+ Foxp3+ regulatory T cells in tumor-infiltrating lymphocytes after treatment with Lactobacillus plantarum IMB 19 (A) or CPS (B). Data were analyzed by nonparametric two-tailed t-test. * P < 0.05, ns: not significant.
[0153] Figure 27 The tumor growth inhibitory activity of Lactobacillus plantarum IMB19 in EMT breast cancer was demonstrated.
[0154] Figure 27 Inset A illustrates the growth kinetics of EMT-6 mammary glands in Balb / c SPF mice with and without Lactobacillus plantarum IMB19 treatment, where data are mean ± SEM and analyzed by two-way ANOVA with Dunnett's multiple comparisons, * P < 0.05, *** P < 0.001; and
[0155] Figure 28 The study demonstrated the activity of CPS in improving the intratumoral infiltration of inflammatory macrophages in B16.F10 melanoma.
[0156] Figure 28 Inset A shows the number and percentage of CD45+CD11c+CD11b+ tumor-infiltrating macrophages after CPS treatment 40 hours post-tumor inoculation.
[0157] Figure 28 small picture B and Figure 28 Inset C shows the active markers (i.e., CD11b, MHC I, MHC II, CD86, and CD40) on tumor-infiltrating macrophages (B) and dendritic cells (C) after CPS treatment.
[0158] Figure 28 Inset plot D shows the percentage of CD8+CD69+ T cells in tumor-draining lymph nodes after CPS treatment. Data are mean ± SEM and analyzed by two-way ANOVA with Dunnett's multiple comparisons (A) or nonparametric two-tailed t-test (B). * P < 0.05, ** P < 0.01, *** P < 0.001.
[0159] Figure 28 small picture E and Figure 28 Inset F shows the active markers (i.e., MHC I, MHC II, iNOS2, CD68, CD40, CD80, and CD86) on mouse peritoneal macrophages treated with CPS (10 μg / ml) in vitro immediately after isolation (E) or 24 hours after IL-4 treatment (F).
[0160] Figure 28 Small figure G shows the results of DAVID pathway analysis of M1 macrophage gene markers in tumor-derived macrophages enriched with CPS- or PBS-treated cells isolated 40 hours after tumor inoculation. Detailed Implementation
[0161] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Generally, the nomenclature used herein is well-known and typical in the art.
[0162] Because symbiotic microorganisms are known to be closely involved in the immune regulatory responses of hosts such as humans, comprehensive research is underway on symbiotic microorganisms (i.e., probiotics) with the ability to enhance or suppress immunity. Among the numerous microbial species that have coexisted with humans throughout evolution, only a very small number have been found to possess immunomodulatory activity, and even within a given microbial species, immunomodulatory activity varies significantly depending on the strain type, or even exhibits opposite effects. Due to the great diversity of activities possessed by microorganisms, and the fact that activity differs for each individual microorganism, there has recently been a surge of interest in postbiotics (such as useful metabolites or effective molecules produced by microorganisms with immunomodulatory activity). In particular, mannose, β-glucan, and microbial-derived polysaccharides are known to have various effects on the host's immune system. However, microbial-derived polysaccharides have also been reported to possess a variety of activities, depending on their type and structure, and polysaccharides such as yeast polysaccharides exhibit both immunomodulatory and immunosuppressive aspects. Therefore, elucidating the immunomodulatory mechanisms of each polysaccharide is crucial for the use of probiotic-derived polysaccharides for immunomodulation in subjects, particularly for clinical treatment in humans. However, reports on the relationship between polysaccharide structure and immunomodulatory activity are scarce.
[0163] The inventors have diligently worked to elucidate the relationship between polysaccharide structure and immunomodulatory activity from the perspective of metabiotics. They have revealed the relationship and mechanism between immunomodulatory activity and the structure of polysaccharides derived from various strains such as Bifidobacterium and yeasts that exhibit immunomodulatory activity, and have filed patent applications (Korean Patent Application No. 2018-0067535 (pending registration), Korean Patent Application No. 2019-0091908, etc.).
[0164] In one embodiment of the present invention, the inventors identified a novel *Lactobacillus plantarum* strain IMB19 from kimchi (a traditional Korean fermented food) that exhibits high immunostimulatory activity and deposited it at the Korean Center for Biological Resources (accession number: KCTC 14337BP).
[0165] In another embodiment of the invention, it has been demonstrated that in a co-culture system designed to include both the innate and acquired immune systems, the strain increases immunostimulatory cytokines (e.g., IFN-γ), inhibits anti-inflammatory cytokines (e.g., IL-10), significantly increases effector T cells, and inhibits Treg production, thereby stimulating the host's immune system and inhibiting tumor growth and proliferation.
[0166] Therefore, one aspect of the present invention relates to a strain of Lactobacillus plantarum IMB19 with accession number KCTC 14337BP.
[0167] The *Lactobacillus plantarum* strain IMB19 of the present invention exhibits excellent immunomodulatory and antitumor activities. More specifically, the strain of the present invention can exhibit various immunomodulatory and / or antitumor activities, such as i) inducing T cell differentiation into inflammatory phenotypes, such as inducing helper T cells and inhibiting Treg cell differentiation, ii) stimulating CD8+ T cells, enhancing their activity, and improving tumor infiltration, iii) inhibiting Treg cell activity, iv) increasing macrophage infiltration in tumors, and v) activating macrophages to become inflammatory cells and reprogramming them from M2 to M1 macrophages.
[0168] The *Lactobacillus plantarum* strain IMB19 (hereinafter abbreviated as *Lactobacillus plantarum* IMB19) of the present invention was isolated from kimchi and identified as a novel strain through 16S rRNA analysis, recA amplification / band comparison, whole genome sequencing, and phylogenetic, morphological and physiological analysis, and has been deposited.
[0169] In this invention, the Lactobacillus plantarum IMB19 strain can be derived from fermented foods, such as kimchi.
[0170] In this invention, the Lactobacillus plantarum IMB19 strain can form small, smooth, and ring-shaped translucent colonies.
[0171] In this invention, the *Lactobacillus plantarum* IMB19 strain can be non-flagellated.
[0172] In this invention, the Lactobacillus plantarum IMB19 strain can form rod-shaped colonies.
[0173] In this invention, the Lactobacillus plantarum IMB19 strain may have a capsule layer.
[0174] In this invention, the *Lactobacillus plantarum* IMB19 strain can be either non-hemolytic or γ-hemolytic.
[0175] In this invention, the Lactobacillus plantarum IMB19 strain can be gelatinase-negative.
[0176] In this invention, the Lactobacillus plantarum IMB19 strain may not produce biogenic amines such as histamine, cadaverine, tyramine and / or putrescine.
[0177] In this invention, the Lactobacillus plantarum IMB19 strain can be kanamycin resistant.
[0178] In this invention, the *Lactobacillus plantarum* IMB19 strain can possess immunomodulatory and / or antitumor activities. More specifically, the *Lactobacillus plantarum* IMB19 strain can exhibit various immunomodulatory and / or antitumor activities, such as i) inducing T cell differentiation into inflammatory phenotypes, such as inducing helper T cells and inhibiting Treg cell differentiation, ii) stimulating CD8+ T cells, enhancing their activity, and improving tumor infiltration, iii) inhibiting Treg cell activity, iv) increasing macrophage infiltration in tumors, and v) activating macrophages to become inflammatory cells and reprogramming them from M2 to M1 macrophages, but the invention is not limited thereto.
[0179] In this invention, the Lactobacillus plantarum IMB19 strain can inhibit tumor growth.
[0180] In one embodiment of the present invention, it has been demonstrated that in animal tumor models fed with the strain, significant immune-enhancing effects and anti-tumor activity are exhibited through various mechanisms, such as stimulating CD8+ T cells, differentiating them in macrophages, phenotype induction, inhibiting Tregs, and improving tumor infiltration of immune cells.
[0181] In another embodiment of the invention, it has been demonstrated that tumor growth is significantly inhibited after treatment with CPS.
[0182] Therefore, another aspect of the present invention relates to a composition for immunomodulation containing the said strain and / or its culture medium as an active ingredient.
[0183] Furthermore, another aspect of the present invention relates to an immunomodulatory method comprising administering the strain and / or its culture medium to a subject.
[0184] Furthermore, another aspect of the invention relates to the use of the strain and / or its culture medium for immunomodulation.
[0185] Furthermore, another aspect of the invention relates to the use of the strain and / or its culture medium for the manufacture of compositions for immunomodulation.
[0186] As used herein, the term "immunomodulation" refers to overcoming immune imbalances in the blood and maintaining immune homeostasis. Maintenance of immune homeostasis is a state in which immune tolerance, which suppresses the immune system, is balanced with an immune response that enhances the immune system. Maintaining this state is essential for the treatment of most diseases, including tumors and cancers. In this invention, the composition is preferably used for immune stimulation.
[0187] In this invention, the composition for immunomodulation can be used for immune stimulation.
[0188] In this invention, the composition for immune regulation may be a composition for immune stimulation or immune enhancement.
[0189] In this invention, the composition used for immune regulation may be a probiotic composition.
[0190] As used herein, the term "probiotic" refers to live microorganisms that, when administered in appropriate amounts, are beneficial to the health of the host (Nat. Rev. Gastroenterol Hepatol 11, 506-514 (2014)). Probiotics act as supplements to the host's gut microbiota and can be characterized by improving intestinal barrier function and modulating the host's immune system.
[0191] In this invention, the probiotic composition may further contain prebiotics.
[0192] In this invention, for the prevention, improvement, or treatment of tumors, infectious diseases, and immune diseases caused by or as symptoms of immunodeficiency / suppression, the immunomodulatory composition can be used as a pharmaceutical composition or a food composition. Here, the dosage and form of use can be appropriately adjusted according to the purpose.
[0193] In this invention, the composition for immunomodulation can be used in combination with other pharmaceutical or food compositions, or can be used as an adjuvant. Examples of other pharmaceutical compositions include, but are not limited to, immunotherapeutic agents related to immunotherapy, immune cell therapy agents, etc. Examples of other food compositions include, but are not limited to, fermented foods, fermentation starters for producing fermented foods, and health functional foods such as nutritional supplements.
[0194] In this invention, in addition to the Lactobacillus plantarum IMB19 strain and / or its culture medium, the composition for immunomodulation may further include other probiotic strains, compounds, adjuvants, additives, carriers, excipients, etc.
[0195] As used herein, the term "culture medium" can refer to the stock culture medium containing the *Lactobacillus plantarum* IMB19 strain of the present invention, and can be used in a comprehensive sense to include all its lysates, centrifugal supernatants or precipitates, concentrates, dried products, etc. The *Lactobacillus plantarum* IMB19 strain of the present invention can be cultured using typical methods for culturing *Lactobacillus* strains. Methods for culturing the strain of the present invention have been exemplarily described in the examples. The culture medium can include natural or synthetic culture media. Examples of carbon sources for the culture medium can include glucose, sucrose, dextrin, glycerol, etc., and examples of nitrogen sources can include peptone, meat extract, yeast, soybean, ammonium salts, nitrates, and other organic or inorganic nitrogen-containing compounds, but the present invention is not limited thereto. The inorganic salts contained in the culture medium can include, but are not limited to, magnesium, manganese, calcium, iron, potassium, etc. In addition to the components of carbon sources, nitrogen sources, and inorganic salts, amino acids, vitamins, nucleic acids, etc., may also be added.
[0196] In this invention, the culture medium may contain *Lactobacillus plantarum* IMB19 strain and / or immunomodulatory active ingredients (e.g., polysaccharides) derived from *Lactobacillus plantarum* IMB19 strain. The strain may be in a liquid or dried state, and the drying method may include, but is not limited to, natural drying, spray drying, and freeze drying.
[0197] Another aspect of the present invention relates to a pharmaceutical composition for the prevention or treatment of tumors or infectious diseases, said pharmaceutical composition containing the Lactobacillus plantarum IMB19 strain or its culture medium as an active ingredient.
[0198] Furthermore, another aspect of the invention relates to a method for preventing or treating tumors or infectious diseases, the method comprising administering the strain and / or its culture medium to a subject.
[0199] Furthermore, another aspect of the present invention relates to the use of the strain and / or its culture medium for the prevention, improvement or treatment of tumors or infectious diseases.
[0200] The present invention also relates to the use of the strain and / or its culture medium for the manufacture of pharmaceutical compositions for the prevention or treatment of tumors or infectious diseases.
[0201] As used herein, the term "tumor" refers to the phenomenon in which cells become autonomous and proliferate excessively by deviating from the body's regulatory mechanisms, or the resulting growths or proliferations. The term "tumor" includes, for example, all benign, pre-malignant, and malignant tumors, and more specific examples include histiocytomas, gliomas, astrocytomas, osteomas, various types of cancer such as lung cancer, small cell lung cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, rectal cancer, pancreatic cancer, breast cancer, skin cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcoma, osteosarcoma, melanoma, lymphoma (Hodgkin's lymphoma, FL, MCL, MZBL, CLL, T-ALL, AML, ALL, etc.), blood cancers, leukemia, psoriasis, bone diseases, fibroproliferative disorders, atherosclerosis, etc., and preferably melanoma, breast cancer, kidney cancer, lung cancer, bladder cancer, and rectal cancer, but the invention is not limited thereto.
[0202] As used herein, the term "infectious disease" refers to a pathogen-related disease induced or exacerbated by infection caused by various pathogens. For example, the infectious disease may be a disease induced or exacerbated by infection caused by viruses, bacteria, fungi, protozoa, parasites, prions, or protein aggregates, but the invention is not limited thereto.
[0203] As used herein, the term "prevention" refers to any effect that can suppress or delay the onset of disease by applying a pharmaceutical composition according to the invention.
[0204] As used herein, the term "treatment" means any effect that improves or beneficially alters the symptoms of a disease by administering a pharmaceutical composition according to the invention.
[0205] The pharmaceutical compositions of the present invention exhibit preventive or therapeutic and anti-inflammatory effects on various diseases through the aforementioned immune-enhancing and / or anti-tumor effects of their active ingredients.
[0206] In addition to containing the Lactobacillus plantarum IMB19 strain or its culture medium of the present invention, the pharmaceutical composition may further contain suitable carriers, excipients and diluents commonly used in pharmaceutical compositions.
[0207] The composition may contain carriers, excipients, and diluents including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylparaben, propylparaben, talc, magnesium stearate, and mineral oil. When formulating the composition, it is typically prepared using diluents or excipients (such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc.).
[0208] The pharmaceutical compositions according to the invention can be formulated and used in various forms according to typical methods. Suitable formulations include tablets, pills, powders, granules, sugar-coated tablets, hard or soft capsules, solutions, suspensions, emulsions, injections, oral formulations (such as aerosols), topical preparations, suppositories, and sterile injectable solutions, but the invention is not limited thereto.
[0209] The pharmaceutical compositions according to the invention can be formulated into suitable dosage forms using pharmaceutically inert organic or inorganic carriers. Specifically, when the formulation is a tablet, coated tablet, sugar-coated tablet, or hard capsule, the formulation may contain lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof. Additionally, when the formulation is a soft capsule, it may contain vegetable oils, waxes, fats, and semi-solid and liquid polyols. Furthermore, when the formulation is in solution or syrup form, it may contain water, polyols, glycerol, and vegetable oils.
[0210] In addition to the carriers described above, the pharmaceutical compositions according to the present invention may further include preservatives, stabilizers, wetting agents, emulsifiers, solubilizers, sweeteners, colorants, osmotic pressure regulators, antioxidants, etc.
[0211] The pharmaceutical composition according to the invention is administered in a pharmaceutically effective amount. In this invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease according to a reasonable benefit / risk ratio suitable for medical treatment, and is determined based on various factors including the type and severity of the patient's disease, drug activity, drug sensitivity, time of administration, route of administration, excretion rate, duration of treatment, and concurrently used drugs, as well as other factors well known in the medical field. The pharmaceutical composition according to the invention can be administered as a single therapeutic agent or in combination with other therapeutic agents, can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered once or multiple times. Taking all the foregoing factors into account, it is important to administer the composition in the minimum amount that yields the maximum effect without side effects, said minimum amount which can be readily determined by those skilled in the art.
[0212] The pharmaceutical compositions of the present invention can be administered to a subject via any of a variety of routes. Administration methods may include, for example, subcutaneous, intravenous, intramuscular, intrauterine, dural, or intracerebral injection. The pharmaceutical compositions of the present invention are determined based on the type of drug as the active ingredient, taking into account various factors such as the disease to be treated, route of administration, patient's age, sex, weight, and severity of the disease.
[0213] The administration method of the pharmaceutical composition according to the invention can be easily selected according to the dosage form, and oral or parenteral administration is possible. The dosage can vary depending on the patient's age, sex, weight, severity of disease, and route of administration.
[0214] The compositions of the present invention can be administered in combination with other treatment regimens or agents. When used for the prevention or treatment of tumors, other therapies or agents are preferably immunotherapy or immune cell therapy agents, but are not limited thereto, and can be used in various combinations according to the clinician's judgment.
[0215] Another aspect of the present invention relates to a food composition for immune enhancement, said food composition containing the Lactobacillus plantarum IMB19 strain or its culture medium of the present invention as an active ingredient.
[0216] Furthermore, another aspect of the invention relates to the use of the strain and / or its culture medium in the manufacture of food compositions for immune enhancement.
[0217] The food composition of the present invention can maintain immune homeostasis by enhancing or improving immune activity.
[0218] The food composition of the present invention can be a health food that exhibits the effect of preventing or improving tumors or infectious diseases.
[0219] As used herein, the term "food" refers to meat, sausage, bread, chocolate, candy, snacks, preserved fruit, pizza, other noodles, chewing gum, dairy products (including ice cream), various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, prebiotics, probiotics, postbiotics, functional foods and health foods, and includes all foods in the general sense.
[0220] The term "health functional food" has the same meaning as the term "food for special health purposes (FoSHU)," and refers to a food with high medicinal and therapeutic effects that has been processed to effectively exhibit bioregulatory functions in addition to nutritional supply. Here, "functional" means to obtain a useful effect for health purposes, such as nutrient regulation or physiological activity related to the structure and function of the human body. The food of the present invention can be manufactured by methods commonly used in the art, and raw materials and components commonly used in the art can be added during the manufacturing process. Furthermore, any food form can be provided without limitation, as long as it is a formulation generally recognized as a food, and the health functional food according to the present invention can be in the form of powder, granules, tablets, capsules, or beverages.
[0221] Health foods refer to foods that, in addition to ordinary foods, have a positive effect on maintaining or promoting health, while health supplements refer to foods intended for health supplementation. In some cases, the terms "health functional foods," "health foods," and "health supplements" are used interchangeably.
[0222] The food composition may further include a physiologically acceptable carrier, with no particular limitation on the type of carrier, and any carrier commonly used in the art may be used.
[0223] Furthermore, the composition may contain additional ingredients commonly used in food compositions to improve aroma, taste, visual appearance, etc. For example, the composition may contain vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folic acid, pantothenic acid, etc. Additionally, the composition may contain minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr), etc. Furthermore, the composition may contain amino acids such as lysine, tryptophan, cysteine, valine, etc.
[0224] In addition, the composition may contain food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder, high-concentration bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar pigments, etc.), color developers (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), flavorings (MSG, etc.), sweeteners (gluconol, cyclamate, saccharin, sodium, etc.), seasonings (vanillin, lactone, etc.), leavening agents (alum, potassium D-tartrate, etc.), reinforcing agents, emulsifiers, thickeners, film-forming agents, gumming agents, defoaming agents, solvents, modifiers, etc. These additives can be selected according to the type of food and can be used in appropriate amounts.
[0225] In addition to the *Lactobacillus plantarum* IMB19 strain or its culture medium of the present invention, the food composition may further contain food supplements acceptable for human consumption and may be used with other foods or food ingredients, and may be used appropriately according to typical methods. The amount of active ingredients contained therein may be appropriately determined according to the purpose of use (prevention, health care, or therapeutic treatment).
[0226] In one embodiment of the present invention, it has been confirmed that capsular polysaccharide is an active ingredient exhibiting the immunomodulatory activity of Lactobacillus plantarum IMB19 of the present invention.
[0227] In another embodiment of the invention, it has been demonstrated that the isolated capsular polysaccharide exhibits excellent immunomodulatory and antitumor activity through various mechanisms such as: i) inducing T cell differentiation into inflammatory phenotypes, such as inducing helper T cells and inhibiting Treg cell differentiation; ii) stimulating CD8+ T cells, enhancing their activity, and improving tumor infiltration; iii) inhibiting Treg cell activity; iv) increasing macrophage infiltration in tumors; and v) activating macrophages to become inflammatory cells and reprogramming them from M2 to M1 macrophages, as in the *Lactobacillus plantarum* IMB19 strain.
[0228] In yet another embodiment of the invention, the capsular polysaccharide is subjected to structural analysis by NMR.
[0229] Therefore, another aspect of the present invention relates to a capsular polysaccharide (CPS) derived from the Lactobacillus plantarum strain IMB19 that has immunomodulatory activity.
[0230] In this invention, the capsular polysaccharide may comprise a polysaccharide having the following formula I.
[0231] [Formula I]
[0232] -[-DBIFGCEHA-] n -
[0233] Here, A and D are galactose.
[0234] B, C, E, G, and H are rhamnose.
[0235] F is N-acetylglucosamine.
[0236] I is glucose, and
[0237] n is an integer of 1 or greater.
[0238] In this invention, the polysaccharide having Formula I is a polymer structure of the repeating unit represented by [-DBIFGCEHA-] in Formula I.
[0239] In this invention, when n in Formula I is 2 or greater, the repeating units can be linked in various ways without limitation, in addition to direct covalent bonding. For example, the repeating units can be linked by chemical bonding, such as glycoside linkage or phosphodiester linkage, or they can be linked via a linker.
[0240] In this invention, when n in Formula I is 2 or greater, the repeating unit ([-DBIFGCEHA-]) can be linked by a glycosidic link (-O-) between A and D.
[0241] In this invention, when n in Formula I is 2 or greater, the repeating unit ([-DBIFGCEHA-]) can be connected by a phosphodiester link between A and D.
[0242] In this invention, when n in Formula I is 2 or greater, the carbon at position 1 in repeating unit A and the carbon at position 6 in repeating unit D can be connected by phosphate diester linkage.
[0243] In this invention, at least one of A and D of Formula I can be phosphorylated, and preferably, in the case of A, the hydroxyl group of the carbon at position 1 is phosphorylated, and in the case of D, the hydroxyl group of the carbon at position 6 is phosphorylated.
[0244] In this invention, the galactose used includes galactose or its derivatives, which are commonly found in nature. For example, in this invention, the galactose may be provided in the form of isomers of α- or β- or D- or L-configurations, preferably α-galactose, and more preferably α-D-galactose, but is not limited thereto.
[0245] In this invention, the rhamnose used includes all rhamnose or its derivatives that are normally found in nature. For example, in this invention, rhamnose may be provided in the form of isomers of α-configuration or β-configuration, or D-configuration or L-configuration, preferably α-rhamnose, and more preferably α-L-rhamnose, but is not limited thereto.
[0246] In this invention, the N-acetylglucosamine used includes all N-acetylglucosamines and their derivatives.
[0247] In this invention, the glucose used includes all typical glucose or its derivatives. For example, in this invention, the glucose may be provided in the form of α-configuration or β-configuration, or D-configuration or L-configuration isomers, preferably glucose having the β-configuration, and more preferably D-glucose, but is not limited thereto.
[0248] In this invention, D and B (DB) and B and I (BI) can be linked by α-1,3-glycoside linkage.
[0249] In this invention, I and F (IF) can be linked by β-1,6-glycoside linkage.
[0250] In this invention, F and G (FG), G and C (GC), C and E (CE), and E and H (EH) can be linked by α-1,2-glycoside linkage.
[0251] In this invention, H and A (HA) can be linked by α-1,6-glycoside linkage.
[0252] In this specification, glycosidic linkages are indicated as α or β depending on the linkage direction, and the adjacent number indicates the number of carbons in the two monosaccharides linked by a glycosidic linkage (-O-). For example, "I and F (IF) are linked by a β-1,6-glycosidic linkage" means that the carbon at position 1 of I and the carbon at position 6 of F are linked by a glycosidic linkage in the β configuration relative to I.
[0253] In this invention, the capsular polysaccharide may comprise a polysaccharide of Formula I, wherein n is an integer of 1 or greater, and may comprise a variety of polysaccharides of Formula I polymerized with various n values. Preferably, the polysaccharide of Formula I is characterized in that n is a value ranging from 1 to 10.
[0254] In one embodiment of the invention, it has been demonstrated that the capsular polysaccharide comprising the polysaccharide of formula I has an average degree of polymerization of about 4 and an average molecular weight of about 6.0 kDa. Each repeating unit ([-DBIFGCEHA-]) has been shown to have a molecular weight (MW) of about 1.5 kDa.
[0255] In this invention, the "average degree of polymerization (average value of n)" of the polysaccharide containing the capsular polysaccharide having Formula I is preferably 1 to 10, and most preferably about 4.
[0256] In this invention, the average molecular weight of the polysaccharide containing the capsular polysaccharide having Formula I can be from 1.5 kDa to 15 kDa, and preferably about 6.0 kDa.
[0257] In one embodiment of the invention, capsular polysaccharides of Formula I contained in capsular polysaccharides are separated from Lactobacillus plantarum strain IMB19 by ion-exchange chromatography using approximately 100 mM NaCl as the eluent. The separation method is described in detail in the examples, but the invention is not limited thereto. The polysaccharides can be obtained using various conventionally known purification methods based on the structure and characteristics of the polysaccharides of Formula I described in this invention.
[0258] In this invention, the capsular polysaccharide may further comprise teichoic acid.
[0259] As demonstrated in one embodiment of the invention, the capsular polysaccharide may further comprise two or more teichoic acids.
[0260] In this invention, the teichoic acid can be of the Gro or Rbo type, and when the capsular polysaccharide further comprises two or more teichoic acids, the teichoic acid can be included in the form of a single type or a mixture of two types.
[0261] In this invention, in addition to the polysaccharide and / or teichoic acid of Formula I, the capsular polysaccharide may further contain other polysaccharides or biomolecules, such as lipids.
[0262] Another aspect of the present invention relates to a method for producing a polysaccharide having immune-enhancing activity, comprising:
[0263] (a) Cultivating the above-mentioned strains; and
[0264] (b) Obtain capsular polysaccharides from the cultured strain.
[0265] In this invention,
[0266] The method may further include (c) obtaining an effective polysaccharide fraction with immunomodulatory activity by performing ion exchange chromatography on the obtained capsular polysaccharide.
[0267] The method for generating capsular polysaccharides and the steps for obtaining effective polysaccharide fractions with immune-enhancing activity of the present invention are described in exemplary detail in the embodiments of the present invention, but are not limited thereto.
[0268] In one embodiment of the present invention, capsular polysaccharides (CPS) derived from Lactobacillus plantarum strain IMB19 are fractionated by ion exchange chromatography using different concentrations of NaCl eluent, and the structure of the polysaccharides contained in each fraction is analyzed by NMR.
[0269] In another embodiment of the invention, significant levels of IFN-γ, TNF-α, IL-6, and IL-12, and negligible levels of IL-10, IL-17, and IL-1β were produced only in CPS-100 purified using 100 mM NaCl, while no significant cytokine production was detected in other fractions (CPS-400 (containing teichoic acid), etc.). This indicates that the effective molecule exhibiting the immunomodulatory activity of Lactobacillus plantarum IMB19 is a polysaccharide (Formula I) with a polymer structure containing specific repeating units in CPS-100.
[0270] Therefore, another aspect of the present invention relates to a polysaccharide represented by the following formula I:
[0271] [Formula I]
[0272] -[-DBIFGCEHA-] n -
[0273] In equation I,
[0274] A and D are galactose.
[0275] B, C, E, G, and H are rhamnose.
[0276] F is N-acetylglucosamine.
[0277] I is glucose, and
[0278] n is an integer of 1 or greater.
[0279] In this invention, the polysaccharide having Formula I is a polymer structure of the repeating unit represented by [-DBIFGCEHA-] in Formula I.
[0280] In this invention, when n in Formula I is 2 or greater, the repeating units can be linked in various ways without limitation, in addition to direct covalent bonding. For example, the repeating units can be linked by chemical bonding, such as glycoside linkage or phosphodiester linkage, or they can be linked via a linker.
[0281] In this invention, when n in Formula I is 2 or greater, the repeating unit ([-DBIFGCEHA-]) can be linked by a glycosidic link (-O-) between A and D.
[0282] In this invention, when n in Formula I is 2 or greater, the repeating unit ([-DBIFGCEHA-]) can be connected by a phosphodiester link between A and D.
[0283] In this invention, when n in Formula I is 2 or greater, the carbon at position 1 in repeating unit A and the carbon at position 6 in repeating unit D can be connected by phosphate diester linkage.
[0284] In this invention, at least one of A and D of Formula I can be phosphorylated, and preferably, in the case of A, the hydroxyl group of the carbon at position 1 is phosphorylated, and in the case of D, the hydroxyl group of the carbon at position 6 is phosphorylated.
[0285] In this invention, the galactose used includes galactose or its derivatives, which are commonly found in nature. For example, in this invention, the galactose may be provided in the form of isomers of α- or β- or D- or L-configurations, preferably α-galactose, and more preferably α-D-galactose, but is not limited thereto.
[0286] In this invention, the rhamnose used includes all rhamnose or its derivatives that are normally found in nature. For example, in this invention, rhamnose may be provided in the form of isomers of α-configuration or β-configuration, or D-configuration or L-configuration, preferably α-rhamnose, and more preferably α-L-rhamnose, but is not limited thereto.
[0287] In this invention, the N-acetylglucosamine used includes all N-acetylglucosamines or their derivatives that are normally found in nature.
[0288] In this invention, the glucose used includes all typical glucose or its derivatives. For example, in this invention, the glucose may be provided in the form of α-configuration or β-configuration, or D-configuration or L-configuration isomers, preferably glucose having the β-configuration, and more preferably D-glucose, but is not limited thereto.
[0289] As used herein, the term "derivative" refers to a compound whose structure is sufficiently similar to that of the compounds disclosed herein, and which, based on this similarity, exhibits the same or similar activity and end use as the claimed compound; or, as a precursor, a compound having a structure derived from a parent compound (e.g., a polysaccharide of Formula I described herein), which is intended to cause the same or similar activity and end use as the claimed compound. Examples of such derivatives may include, but are not limited to, salts, isomers, esters, amides, salts of esters or amides, N-oxides, etc., of the parent compound.
[0290] In this invention, D and B (DB) and B and I (BI) of Formula I can be linked by α-1,3-glycoside linkage.
[0291] In this invention, I and F (IF) of Formula I can be linked by β-1,6-glycoside linkage.
[0292] In this invention, F and G (FG), G and C (GC), C and E (CE), and E and H (EH) of Formula I can be linked by α-1,2-glycoside linkage.
[0293] In this invention, H and A (HA) of Formula I can be linked by α-1,6-glycoside linkage.
[0294] In this specification, the connection is indicated as α or β depending on the direction of connection, and the adjacent number refers to the corresponding number of carbons connected in the (-O-) connection between the two monosaccharides.
[0295] In this invention, n in Formula I is an integer of 1 or greater, preferably an integer from 1 to 10, and more preferably 4.
[0296] In this invention, the polysaccharide may have the structure of Formula II.
[0297] [Formula II]
[0298]
[0299] n is an integer of 1 or greater.
[0300] In this invention, n in Formula II is preferably an integer from 1 to 10, and more preferably n is 4.
[0301] In one embodiment of the invention, it has been demonstrated that the polysaccharides comprising Formula I contained in CPS-100 (effective fraction of capsular polysaccharide) have an average degree of polymerization of about 4 and an average molecular weight of about 6.0 kDa. Each repeating unit ([-DBIFGCEHA-]) has been shown to have a molecular weight (MW) of about 1.5 kDa.
[0302] In this invention, depending on the degree of polymerization, the degree of phosphorylation, etc., the polysaccharide having Formula I can have a molecular weight of at least about 1.5 kDa, preferably about 1.5 kDa to about 15 kDa, and more preferably about 4 kDa.
[0303] In this invention, the polysaccharide may be derived from the Lactobacillus plantarum strain IMB19 with accession number KCTC 14337BP.
[0304] In this invention, the polysaccharide having Formula I can possess immunomodulatory and / or antitumor activities. More specifically, the *Lactobacillus plantarum* IMB19 strain can possess various immunomodulatory and antitumor activities, such as i) inducing T cell differentiation into inflammatory phenotypes, such as inducing helper T cells and inhibiting Treg cell differentiation, ii) stimulating CD8+ T cells, enhancing their activity, and improving tumor infiltration, iii) inhibiting Treg cell activity, iv) increasing macrophage infiltration in tumors, and v) activating macrophages to become inflammatory cells and reprogramming them from M2 to M1 macrophages, but not limited to these mechanisms.
[0305] In this invention, the polysaccharide having Formula I can inhibit tumor growth.
[0306] In this invention, the polysaccharide can be produced / isolated by those skilled in the art using the strains of this invention, and the polysaccharide of this invention can be induced or synthesized by other chemical or biological methods.
[0307] Furthermore, it is evident that the structure of CPS can be modified to improve the pharmacokinetic and / or pharmacodynamic properties of the polysaccharides of the present invention or their clinical formulation (e.g., solubility). For example, modifications can be made i) by adding at least one functional group, ii) by modifying the carbon chain, iii) by adding at least one hydrogen or hydroxyl group, iv) by modifying the terminal groups (e.g., by adding signaling molecules such as dyes), and v) by binding to other known sugar molecules (e.g., formulations for oral or systemic delivery), but the invention is not limited thereto.
[0308] Therefore, the polysaccharides of the present invention are not limited to polysaccharides having formula I or formula II, and are conceptually understood to include all variants, derivatives, analogs, etc. having formula I or formula II, as long as they exhibit the immunostimulatory and immunoenhancing effects of the present invention.
[0309] Therefore, another aspect of the present invention relates to an immunomodulatory composition containing a polysaccharide having formula I as an active ingredient.
[0310] Furthermore, another aspect of the present invention relates to an immunomodulatory method comprising administering the polysaccharide to a subject.
[0311] Furthermore, another aspect of the invention relates to the use of the polysaccharide for immune regulation.
[0312] Furthermore, another aspect of the invention relates to the use of the polysaccharide in the manufacture of compositions for immunomodulation.
[0313] Unless a specific definition of the term is provided, these terms shall be understood to have the meaning as understood by those skilled in the art or as defined by other aspects of the invention.
[0314] In this invention, the composition for immune regulation can be used for immune stimulation or immune enhancement.
[0315] In this invention, the composition for immune regulation may be a composition for immune stimulation or immune enhancement.
[0316] In this invention, for the prevention, improvement, or treatment of tumors, infectious diseases, and immune diseases caused by or as symptoms of immunodeficiency / suppression, the composition for immunomodulation can be prepared and used in the form of a pharmaceutical composition or a food composition. Here, the dosage and form of use can be appropriately adjusted according to the purpose.
[0317] In one embodiment of the invention, the half-maximum effective concentration (EC50) of the polysaccharide was confirmed to be 3.16 μM. Therefore, it is preferred that the composition of the present invention for immunomodulation contains a polysaccharide in an amount of 3.16 μM or more.
[0318] In this invention, the composition for immunomodulation can be used in combination with other pharmaceutical or food compositions, or can be used as an adjuvant. Examples of other pharmaceutical compositions include, but are not limited to, immunotherapeutic agents and immune cell therapy agents related to immunotherapy. Examples of other food compositions include, but are not limited to, fermented foods and health functional foods such as nutritional supplements.
[0319] In this invention, in addition to the polysaccharide of this invention, the composition for immunomodulation may further include other probiotic strains, compounds, adjuvants, additives, carriers, excipients, etc.
[0320] Another aspect of the invention relates to a pharmaceutical composition for the prevention or treatment of tumors or infectious diseases, comprising a polysaccharide of formula I of the invention as an active ingredient.
[0321] Furthermore, another aspect of the invention relates to a method for preventing or treating tumors or infectious diseases, comprising administering the polysaccharide to a subject.
[0322] Furthermore, another aspect of the invention relates to the use of the polysaccharide for the prevention, improvement, or treatment of tumors or infectious diseases.
[0323] Furthermore, the present invention relates to the use of the polysaccharide in the manufacture of pharmaceutical compositions for the prevention or treatment of tumors or infectious diseases.
[0324] As used herein, the term "tumor" refers to the phenomenon in which cells become autonomous and proliferate excessively by deviating from the body's regulatory mechanisms, or the resulting growths or proliferations. The term "tumor" includes, for example, all benign, pre-malignant, and malignant tumors, and more specific examples include histiocytomas, gliomas, astrocytomas, osteomas, various types of cancer such as lung cancer, small cell lung cancer, gastric cancer, gastrointestinal cancer, intestinal cancer, colon cancer, rectal cancer, pancreatic cancer, breast cancer, skin cancer, ovarian cancer, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, brain cancer, sarcomas, osteosarcomas, melanomas, lymphomas (Hodgkin's lymphoma, FL, MCL, MZBL, CLL, T-ALL, AML, ALL, etc.), blood cancers, leukemia, psoriasis, bone diseases, fibroproliferative disorders, atherosclerosis, etc., but the invention is not limited thereto.
[0325] As used herein, the term "infectious disease" refers to a pathogen-related disease induced or exacerbated by infection caused by various pathogens. For example, the infectious disease may be a disease induced or exacerbated by infection caused by viruses, bacteria, fungi, protozoa, parasites, prions, or protein aggregates, but the invention is not limited thereto.
[0326] The pharmaceutical compositions of the present invention exhibit preventive or therapeutic effects on various diseases and anti-inflammatory effects through the aforementioned immune-enhancing and / or antitumor effects of the polysaccharide having formula I as its active ingredient.
[0327] In addition to containing a polysaccharide of formula I as its active ingredient, the pharmaceutical composition may further include suitable carriers, excipients and diluents commonly used in pharmaceutical compositions.
[0328] The composition may contain carriers, excipients, and diluents including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylparaben, propylparaben, talc, magnesium stearate, and mineral oil. When formulating the composition, it is typically prepared using diluents or excipients (such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc.).
[0329] The pharmaceutical compositions according to the invention can be formulated and used in various forms according to typical methods. Suitable formulations include tablets, pills, powders, granules, sugar-coated tablets, hard or soft capsules, solutions, suspensions, emulsions, injections, oral formulations (such as aerosols), topical preparations, suppositories, and sterile injectable solutions, but the invention is not limited thereto.
[0330] The pharmaceutical compositions according to the invention can be formulated into suitable dosage forms using pharmaceutically inert organic or inorganic carriers. Specifically, when the formulation is a tablet, coated tablet, sugar-coated tablet, or hard capsule, the formulation may contain lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof. Additionally, when the formulation is a soft capsule, it may contain vegetable oils, waxes, fats, and semi-solid and liquid polyols. Furthermore, when the formulation is in solution or syrup form, it may contain water, polyols, glycerol, and vegetable oils.
[0331] In addition to the carriers described above, the pharmaceutical compositions according to the present invention may further include preservatives, stabilizers, wetting agents, emulsifiers, solubilizers, sweeteners, colorants, osmotic pressure regulators, antioxidants, etc.
[0332] The pharmaceutical composition according to the invention is administered in a pharmaceutically effective amount. In this invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease according to a reasonable benefit / risk ratio suitable for medical treatment, and is determined based on various factors including the type and severity of the patient's disease, drug activity, drug sensitivity, time of administration, route of administration, excretion rate, duration of treatment, and concurrently used drugs, as well as other factors well known in the medical field. The pharmaceutical composition according to the invention can be administered as a single therapeutic agent or in combination with other therapeutic agents, can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered once or multiple times. Taking all the foregoing factors into account, it is important to administer the composition in the minimum amount that yields the maximum effect without side effects, said minimum amount which can be readily determined by those skilled in the art.
[0333] The pharmaceutical compositions of the present invention can be administered to a subject via any of a variety of routes. Administration methods may include, for example, subcutaneous, intravenous, intramuscular, intrauterine, dural, or intracerebral injection. The pharmaceutical compositions of the present invention are determined based on the type of drug as the active ingredient, taking into account various factors such as the disease to be treated, route of administration, patient's age, sex, weight, and severity of the disease.
[0334] The administration method of the pharmaceutical composition according to the invention can be easily selected according to the dosage form, and oral or parenteral administration, or local or systemic administration, is possible. The dosage can vary depending on the patient's age, sex, weight, severity of disease, and route of administration.
[0335] The compositions of the present invention can be administered in combination with other treatment regimens or agents. When used for the prevention or treatment of tumors, other therapies or agents are preferably immunotherapy or immune cell therapy agents, but are not limited thereto, and can be used in various combinations according to the clinician's judgment.
[0336] In yet another aspect, the present invention relates to a food composition for immune enhancement containing a polysaccharide having formula I as an active ingredient.
[0337] Furthermore, in yet another aspect, the invention relates to the use of the polysaccharide in the manufacture of food compositions for immune enhancement.
[0338] The food composition of the present invention can maintain immune homeostasis by enhancing or improving immune activity.
[0339] The food composition of the present invention can be a health food that exhibits the effect of preventing or improving tumors or infectious diseases.
[0340] The food composition may further include a physiologically acceptable carrier, with no particular limitation on the type of carrier, and any carrier commonly used in the art may be used.
[0341] Furthermore, the composition may contain additional ingredients commonly used in food compositions to improve aroma, taste, visual appearance, etc. For example, the composition may contain vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folic acid, pantothenic acid, etc. Additionally, the composition may contain minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr), etc. Furthermore, the composition may contain amino acids such as lysine, tryptophan, cysteine, valine, etc.
[0342] In addition, the composition may contain food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder, high-concentration bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar pigments, etc.), color developers (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), flavorings (MSG, etc.), sweeteners (gluconol, cyclamate, saccharin, sodium, etc.), seasonings (vanillin, lactone, etc.), leavening agents (alum, potassium D-tartrate, etc.), reinforcing agents, emulsifiers, thickeners, film-forming agents, gumming agents, defoaming agents, solvents, modifiers, etc. These additives can be selected according to the type of food and can be used in appropriate amounts.
[0343] In addition to the polysaccharide of Formula I as its active ingredient, the food composition may further contain human-acceptable food supplements and may be used with other food or food ingredients, and may be used appropriately according to typical methods. The amount of the active ingredient contained therein may be appropriately determined according to the purpose of use (prevention, health care, or therapeutic treatment).
[0344] In one embodiment of the present invention, it has been demonstrated that the strains and polysaccharides derived from the strains according to the present invention induce the expression of IFN-γ in cells and inhibit the expression of IL-10 both in vivo and in vitro, thereby stimulating and enhancing the immune response.
[0345] In another embodiment of the invention, it has been demonstrated that the strain and the polysaccharide derived from the strain can activate CD8+ T cells via DC, and that CD8+ T cell activation is significantly reduced in the absence of the MyD88 signaling system.
[0346] In yet another embodiment of the invention, it has been demonstrated that Th17 cells can be induced by co-culturing DCs induced by the strain and strain-derived polysaccharides with naive CD4+ T cells.
[0347] Therefore, another aspect of the present invention relates to a method for generating inflammatory T cells, comprising:
[0348] (a) Initiating antigen-presenting cells using *Lactobacillus plantarum* strain IMB19 and / or polysaccharides of formula I; and
[0349] (b) Co-culture the antigen-presenting cells induced by the above with T cells.
[0350] As used herein, the term "antigen-presenting cell" refers to a cell that differentiates by receiving an antigen, processing it, and presenting antigen-derived fragments along with antigen-presenting molecules (such as MHC class ± molecules) to T cells. Examples of such antigen-presenting cells include, but are not limited to, macrophages, B cells, dendritic cells (DCs), Langerhans cells, etc.
[0351] In this invention, the T cells in step (b) are preferably naive T cells, more preferably naive CD8+ T cells or naive CD4+ T cells, but are not limited thereto.
[0352] As used herein, the term "inflammatory T cell" refers to a T cell that directly or in the pre-inflammatory stage induces or enhances an immune response. Preferably, the inflammatory T cell is a cytotoxic T cell or a helper T cell (Th cell), more preferably an IFN-γ+ CD8+ T cell or a CD4+ RORγ+ Th17 cell.
[0353] Therefore, yet another aspect of the present invention relates to a cell therapy agent for the prevention or treatment of tumors or infectious diseases, which contains inflammatory T cells generated by the above-described method as an active ingredient.
[0354] In one embodiment of the invention, it has been demonstrated that when splenic macrophages or M2 phenotype macrophages are exposed to CPS, MHC I, MHC II, CD68, iNOS2, and CD40 are significantly upregulated, enabling the reprogramming of immunosuppressive M2 phenotype macrophages into M1 phenotype macrophages in the tumor microenvironment.
[0355] Therefore, another aspect of the present invention relates to a method for generating M1 phenotype macrophages, comprising treating macrophages with Lactobacillus plantarum strain IMB19 and / or a polysaccharide having formula I and obtaining activated M1 phenotype macrophages, thereby differentiating the macrophages into M1 phenotype macrophages.
[0356] As used in this article, the term "macrophage" refers to a type of white blood cell that can engulf and digest pathogens, foreign substances, microorganisms, cancer cells, abnormal proteins, etc., and in addition to the innate immune response, it also acts as an antigen-presenting cell for adaptive immunity.
[0357] Macrophages are classified into M1 phenotype macrophages, which are inflammatory macrophages, and M2 phenotype macrophages, which are anti-inflammatory macrophages and participate in the balance between immune stimulation and suppression. Specifically, M2 phenotype macrophages have been reported to promote tumor growth (Ann. Oncol. 28, xii18-xii32 (2017); Front Oncol. 9, 421 (2019)). M1 phenotype macrophages generally refer to macrophages that are activated through IFN-γ secreted by NK cells or Th1 cells, the MyD88 pathway recognized by PAMPs via TLRs, and thus stimulate and induce immune responses, such as antigen presentation, induction of inflammatory genes and chemokine secretion, etc. M2 phenotype macrophages (immunosuppressive macrophages) are macrophages differentiated from IL-4, IL-13, etc., exhibiting immunosuppressive activity and participating in tissue remodeling and wound healing.
[0358] In this invention, the macrophages in step (a) can be naive macrophages or M2 phenotype macrophages.
[0359] In this invention, M1 phenotype macrophages include, but are not limited to, macrophages activated into an inflammatory phenotype to stimulate or induce an immune response. M1 phenotype macrophages can be classified according to changes in gene expression profiles; for example, M1 phenotype macrophages may be characterized by upregulated expression of at least one of MHC I, MHC II, CD68, iNOS2, and CD40, but this invention is not limited thereto.
[0360] As used in this article, the expression "macrophage differentiation" refers to the activation or transformation of macrophages from their existing gene expression profile to exhibit a different gene expression profile. The use of the term "differentiation" includes not only the activation or polarization of naive macrophages, but also the reprogramming of macrophages that have already been activated and exhibit a specific phenotype (e.g., the M1 or M2 phenotype).
[0361] As used in this article, the term "upregulation" refers to an improvement in the expression of a specific gene or protein compared to the pre-macrophage phenotype.
[0362] Therefore, yet another aspect of the present invention relates to a cell therapy agent for the prevention or treatment of tumors or infectious diseases, which contains inflammatory macrophages produced by the above-described method as an active ingredient.
[0363] Example
[0364] A better understanding of the present invention can be obtained through the following embodiments. These embodiments are for illustrative purposes only and should not be construed as limiting the scope of the invention, as will be apparent to those skilled in the art.
[0365] Example 1: Materials and Methods
[0366] 1. Bacterial culture and identification
[0367] The kimchi was homogenized to obtain its suspension. Then, serial dilutions were performed, streaked onto MRS broth and agar, and incubated at 37°C for 48 hours to isolate colonies, which were then further cultured for various analyses.
[0368] Lactobacillus plantarum IMB19 was cultured in MRS broth at 37°C for 24–36 hours. For TEM (transmission electron microscopy), the bacteria were cultured, streaked on MRS-1.5% agar (Neogen Corp., USA), and incubated for 24–30 hours. Bacterial colonies were dropped onto a 2000-mesh graphene-coated copper grid. TEM imaging was performed using a JEOL1220 and a Hitachi HT7700 at 80 kV.
[0369] For identification, the cell morphology of the selected isolates was observed under a microscope, their genetic characteristics were analyzed using genomic DNA, and 16S rRNA was sequenced using Macrogen (Korea).
[0370] The 16S rRNA gene was amplified by direct PCR using universal primers: forward (27F primer) 5'-AGAGTTTGATCMTGGCTCAG-3' and reverse (1492R primer) 5'-TACGGYTACCTTGTTACGACTT-3'.
[0371] 2. Experiments based on primary cells
[0372] 2-1. In vitro spleen cell stimulation
[0373] All animal experiments and procedures were conducted in accordance with ethical guidelines and with the approval of the POSTECH (Pohang University of Science and Technology) Animal Care and Use Committee. C57BL / 6 mice were housed and bred in a pathogen-free animal barrier facility and used at 6–8 weeks of age. Spleens were harvested and gently ground to release splenocytes. Cells were suspended, RBCs were lysed with ammonium chloride buffer, and resuspended in complete RPMI medium (Welgene, South Korea) containing 10% FBS (Hy-Clone, Australia). Cells were seeded at a density of 200 kJ / well in 200 μL of medium / well containing 10 ng / mL anti-CD3 (Bio-xCell, USA) and 2.5 ng / mL GM-CSF (Peprotech, USA) in 96-well plates. Add fractionated CPS-100, unfractionated total CPS (tCPS), LPS (lipopolysaccharide derived from E. coli O111:B4, Invivogen, USA), and culture medium as needed, then incubate at 37°C and 5% CO2 for 48 hours. Following the manufacturer's instructions, collect the supernatant after centrifugation and freeze for cytokine estimation using an enzyme-linked immunosorbent assay (ELISA, e-Bioscience, Ready-SET-Go! ELISA kit).
[0374] 2-2. Immune cell co-culture system
[0375] Spleen cells were isolated as described above. CD11c+ APCs (MiltenyiBiotec) and naive CD4+ T cells (Stem Cell Technologies) were isolated according to the manufacturer's protocol. APCs were cultured with probiotic strains at 37°C and 5% CO2 for 18 to 20 hours. The probiotic strains were then washed, and the induced APCs and CD4+ T cells were co-cultured with them under specific conditions.
[0376] 3. Safety Evaluation
[0377] 3-1. Hemolysis Test
[0378] Lactobacillus plantarum IMB19 was grown under optimal growth conditions, streaked on 5% sheep blood agar (Hanil, Komed), and then incubated for 48 hours. Alpha (α)2 hemolysis was considered as partial degradation of hemoglobin in erythrocytes (not representing actual hemolysis), beta (β) hemolysis (observed as a clear area on the agar plate) was considered as complete degradation of hemoglobin in erythrocytes, and gamma (γ) hemolysis was considered as no hemolysis. Bacillus cereus ATCC 27348 was used as a positive control.
[0379] 3-2. Gelatin Degradation Test
[0380] The basic protocol was performed according to ASM scientific recommendations (Dela Cru et al., 2012). *Lactobacillus plantarum* IMB19, grown under optimal conditions, was inoculated into gelatin medium using an inoculation loop and cultured at 30°C for up to 5 days, with daily checks for gelatin liquefaction and bacterial growth. Gelatin typically liquefies at temperatures equal to or above 28°C. The tubes were stored in a refrigerator for 30 minutes to determine if liquefaction was due to gelatinase activity. The tubes were then tilted to observe whether the gelatin had degraded. When gelatin degrades, it remains liquid even after exposure to low temperatures. *Bacillus cereus* ATCC 11778 was used as a positive control.
[0381] 3-3. Biogenic Amine Analysis
[0382] Lactobacillus plantarum IMB19 was grown under optimal conditions and streaked on a special medium containing precursors of histamine, cadaverine, tyramine, and putrescine, according to Bover-cid and Holzapfel (Bover-cid et al., 1999), followed by incubation at 37°C, 30°C, and 23°C for 4 days. The analytical results were then determined by observing changes in the color of the medium. Escherichia coli ATCC 25922 was used as a positive control. Cultures were performed on agar using a basal medium containing any one of ornithine, lysine, tyrosine, and histidine, as well as bromocresol purple indicator.
[0383] 3-4. Antibiotic resistance test
[0384] The basic protocol was conducted according to ISO recommendation (ISO-10932, 2010). The minimum inhibitory concentration (MIC) of the strain against the antibiotic was evaluated using the broth dilution method.
[0385] In the microdilution of cultures, test organisms were cultured individually in the culture medium and all organisms were washed with 1X PBS. The bacterial solutions washed with PBS were adjusted to an optical density (OD) of 0.01–0.02 at 600 nm. 10 μL (1x10⁻¹⁰) of the bacterial solution was then used to prepare the culture. 5 -2x10 5 CFU strains were inoculated into 96-well plates containing 200 μL LSM broth and antibiotics.
[0386] A strain is considered susceptible when it is inhibited at a specific antibiotic concentration equal to or below the cutoff value set by the European Food Safety Authority (EFSA, 2018), and is considered resistant when it is not inhibited at a specific antibiotic concentration above the cutoff value established by regulations.
[0387] 4. Isolation of crude capsular polysaccharide (CPS)
[0388] Crude CPS were isolated using a modified form of the method described in the conventional description (Verma et al., 2018). Bacterial cultures were centrifuged and sonicated for 15 minutes using a Branson digital sonicator with 10% amplitude and 10-sec pulses. The supernatant was treated overnight at 4°C with trichloroacetic acid (0.5% w / v). The sample was centrifuged at 6000 rpm for 20 minutes, and 100% ethanol was added to the supernatant at a 3:1 ratio to precipitate the crude polysaccharide at -20°C. The precipitate was resuspended in Tris buffer (100 mM, Sigma Aldrich, USA) in endotoxin-free distilled water containing magnesium chloride (20 mM, Sigma Aldrich) and calcium chloride (20 mM, Sigma Aldrich), and then treated with DNase (0.1 mg / mL, Roche, Germany) and RNase (0.4 mg / mL, Sigma Aldrich, USA) at 37°C for 4–6 hours. Streptomycin (0.3 mg / mL, Sigma-Aldrich, USA) was added to degrade protein contaminants, followed by overnight incubation at 4°C. Total protein, including the added enzyme, was removed by treating the sample with trichloroacetic acid (1%–2% w / v) at 37°C for 30 minutes. All polysaccharides in the protein-free sample were reprecipitated by ethanol precipitation. The precipitate was resuspended in endotoxin-free water and dialyzed at 4°C for 48 hours, with water changes twice daily (MW cutoff 12,000 Da). Total CPS fraction was obtained by freeze-drying, with a final yield of 20 mg / L culture.
[0389] 5. GC-MS Analysis Conditions
[0390] All chemical derivatives were analyzed by gas-liquid chromatography (GLC-MS) using an Agilent 7820A (Santa Clara, California, USA) equipped with a mass-selective detector 5973N and a Zebron ZB-5 capillary column (Phenomenex, 30 m x 0.25 mm id, membrane thickness: 0.25 μm, flow rate: 1 mL / min, and He as carrier gas). Electron collision mass spectrometry was recorded at an ionization energy of 70 eV and an ionization current of 0.2 mA. The temperature program used was as follows: 150°C for 5 min, from 150°C to 300°C at a rate of 10°C / min, and at 300°C for 12 min.
[0391] 6. Obtaining NMR parameters
[0392] To perform structural analysis on the isolated polysaccharides, NMR spectra were recorded in D2O using a Bruker 600 MHz spectrometer equipped with a reverse-biased cryogenic probe tilted along the Z-axis. Spectra were measured at 298 K or 310 K using acetone (…). 1 H2.225 ppm; 13 C 31.45 ppm) was used as an internal standard for correction, obtained using Topspin 2.0 software (Bruker), and processed and studied using Topspin 3.6. 1 H- 1 H DQ-COSY (dual quantum COZY spectrum, hereinafter referred to as COSY), TOCSY, and NOESY spectra were collected using a dataset of 2048 x 512 points (t1 x t2), and the TOCSY and NOESY spectra were collected through 24 scans with mixing times of 100 ms and 200 ms, respectively. Heterogeneous nuclei 1 H- 13 C HSQC, HMBC and HSQC-TOCSY spectra 1 The H-detection mode was performed using a dataset of 2048 x 512 points. During the selection step, HSQC and HSQC-TOCSY were performed with multiple edits to distinguish the CH2 density from other densities. A low-pass J filter was used to suppress single-bond correlations, HMBC was optimized for long-range coupling constants, and a 60 ms delay was used for the evolution of long-range correlations. For HSQC-TOCSY, the mixing time was set to 100 ms. In all two-dimensional tests, the data matrix was expanded to 4092 x 2048 points and transformed by applying either a qsine or sine window function.
[0393] 7. Animal and mouse tumor models
[0394] C57BL / 6 and Balb / c mice were purchased and housed in the POSTECH animal facility. Pmel-1 TCR transgenic, MyD88- / -, and IL-6- / - mice were purchased from Jackson Lab and maintained in the POSTECH animal facility. The C57BL / 6-derived melanoma cell line B16.F10 and the Balb / c-derived breast cancer cell line EMT-6 were obtained from ATCC and maintained according to the provided protocol. Syngenetic tumor models were obtained by subcutaneous injection of 200,000 B16.F10 tumor cells or 500,000 EMT-6 cells. Tumor size was measured every two days until the endpoint, and tumor volume was calculated using length x width 2 x 0.5. For initial infiltration analysis of innate immune cells, tumor cells were subcutaneously injected at 5 ml / mouse and analyzed after 40 hours. All laboratory animal procedures were performed with the approval of the Institutional Animal Management and Use Committee (IACUC) of POSTECH.
[0395] 8. Cell-based in vitro assay methods
[0396] Total cells harvested from the spleen and / or lymph nodes were used for whole spleen cell culture or magnetic bead separation (MiltenyiBiotec) to enrich CD11c+ dendritic cells, naive CD8+ T cells, or naive CD4+ T cells. Total spleen cells (200,000 cells / well) were cultured with bacteria at a 1:1 ratio in 96-cell plates, and the supernatant was harvested after 48 hours for ELISA (eBioscience Ready-SET-Go! kit). CD11c+ dendritic cells (200,000 cells / well) were induced with bacteria at an appropriate ratio for 18 to 20 hours, washed, and T cells (200,000 cells / well) were added and cultured for 72 hours. As shown, CD8+ T cells were stimulated with 0.01 μg / ml anti-CD3 (BioXCell) and 2.5 ng / ml GM-CSF (Peprotech), and CD4+ T cells were stimulated with 0.1 μg / ml anti-CD3, 10 ng / ml GM-CSF, 100 U / ml IL2 and TGFβ (Peprotech).
[0397] For peritoneal macrophages, cells were harvested 5 days after intraperitoneal injection of 2% Biogel (Bio-Rad) and then cultured in vitro with 10 ng / ml recombinant mouse MCSF (Peprotech). To selectively activate macrophage polarization, cells were supplemented with IL-4 (Peprotech) for 24 hours and then treated with CPS, LPS (lipopolysaccharide derived from E. coli O111:B4, Invivogen), or Pam3CSk4 (Sigma).
[0398] 9. Metagenomic analysis and whole-genome sequencing
[0399] Genomic analysis of fecal particles from tumor-bearing SPF mice was outsourced to Macrogen (Korea). Whole-genome sequencing of bacteria was performed on the Illumina platform (Macrogen (Korea),) and bacterial culture samples were sent directly for analysis. Bioinformatics analysis was also outsourced to Macrogen.
[0400] 10. Classification and gene expression profile analysis of tumor-infiltrating macrophages
[0401] 500 μg of CPS was injected into mice twice at 24-hour intervals, followed by subcutaneous inoculation with 5 x 10⁵ CPS. 6 B16.F10 tumor cells. Forty hours after tumor inoculation, intact tumors, including infiltrating immune cells, were digested into single-cell suspensions in liberase. Samples were collected from 5–10 mice in the same treatment group and stained with FixableViability-ef506 (eBioscience), CD45-AF488 (BioLegend, 30-F11), CD3-ef450 (eBioscience, 145-2C11), CD19-PB (eBioscience, 1D3), IA / IE-PECy7 (BioLegend, M5 / 114.15.2), CD11c-PE (eBioscience, N418), and CD11b-PerCpCy5.5 (BD, M1 / 70). Live CD45 cells were then stained. + CD3 - CD19 - MHCII hi CD11c + CD11b +Macrophages were placed in FBS-supplemented medium, centrifuged, and stored in TRIzol (Sigma). Gene expression profiles of the samples were analyzed in Macrogen, the mean fold change in gene transcription levels between treatment groups was calculated, and genes with a fold change of 1.5 or greater between two comparisons were entered into DAVID v6.7 (a database for annotation, visualization, and comprehensive discovery, v6.7) for pathway analysis. Genes identified with significantly enhanced immune function were displayed on heatmaps (p < 0.05).
[0402] 11. In vivo cytotoxicity assay of Listeria monocytogenes
[0403] Analysis was performed using standard, known methods. Specifically, Listeria monocytogenes expressing the OVA peptide (LM-OVA) was injected into C57 / B16 mice at a dose of 5000 CFU / mouse. Mice were fed with Lactobacillus plantarum strain IMB19 every two days. On day 6, spleen cells from juvenile C57 / B16 mice were pulsed with the OVA peptide, and cells stained with or without the peptide pulse were mixed at a 1:1 ratio with CFSE or CTV and administered intravenously to the infected mice. Two hours later, the mice infected with LM-OVA were sacrificed, spleen cells / lymph nodes were harvested, and the cell death rate of the peptide-pulned spleen cells was determined by flow cytometry.
[0404] 12. Purification using chromatography
[0405] Total capsular polysaccharides (tCPS: 28 mg) isolated were purified by anion exchange Q-Sepharose rapid flow assay (GE Healthcare; V = 4.4 mL, flow rate: 16 mL / h). The resin was packed, washed with 1 M NaCl, and equilibrated with 10 volumes of 10 mM NaCl. The total capsular polysaccharides (tCPS) were then dissolved in 10 mM NaCl (5 mL) and adsorbed onto the resin. Elution was performed stepwise by adding 16 mL of NaCl sequentially (10 mM, 100 mM, 200 mM, 400 mM, 700 mM, and 1000 mM). The eluents eluted with each NaCl concentration were collected, desalted by dialysis (cutoff 1 kDa), and lyophilized. The six fractions eluted at the corresponding NaCl concentrations were labeled CPS-X (X is the NaCl concentration used for elution, in mM).
[0406] The molecular weight measurements of CPS-100 were extrapolated using an Agilent 1100 HPLC system and a TSK G-5000 PWXL size size size exclusion column (30 cm x 7.8 mm). The column was equilibrated with 50 mM NH4HCO3 as the eluent (flow rate = 0.8 mL / min), and the eluent was monitored using a refractive index detector. The column was calibrated by injecting 50 μL of 1 mg / mL dextran standards with known molecular weights (12 kDa, 50 kDa, 150 kDa, and 670 kDa, respectively). The logarithm of the molecular weight was plotted relative to the elution volume, and the molecular weight (MW) of the polysaccharides was calculated using the established linear relationship (LogPM = −0.811 mL + 11.7; R² = 0.98).
[0407] 13. Statistical Analysis
[0408] Tumor growth curves were analyzed using two-way ANOVA, with the Sidak multiple comparison test used for comparisons between two groups, the Dunnett multiple comparison test used for comparisons between multiple groups and controls, or the Tukey multiple comparison test used for comparisons between two or more groups. For other comparisons, unpaired Student's t-tests were used when comparing two groups, and Bonferroni correction and one-way ANOVA were used for comparisons between two or more groups. P < 0.05 was considered statistically significant (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). Statistical analysis was performed using GraphPad PRISM v8.0. Flow cytometry data were analyzed using Flow-jo software v10.1.
[0409] Example 2: Isolation and identification of Lactobacillus plantarum IMB19
[0410] Lactobacillus plantarum IMB19 was isolated from homemade kimchi fermented using microorganisms derived from the raw materials. To form Lactobacillus colonies, serially diluted kimchi suspensions were streaked onto MRS broth plates (De Man, Rogosa, and Sharpe broth, Becton-Dickinson, USA). Single colonies were isolated and cultured further in MRS broth. Because the strains could not be distinguished from each other based on colony morphology, PCR and 16S rRNA sequencing were performed on 14 isolated bacteria, and sequence similarity was confirmed using BLAST from NCBI. All isolated bacteria were found to be lactic acid bacteria (LAB). Among the isolated bacteria, strains with at least 99% similarity to Lactobacillus plantarum were identified, and many isolated bacteria were also confirmed to have 99% similarity to Weissella koreensis. These results are consistent with the conventional reporting that Lactobacillus plantarum and Weissella koreensis are the dominant species in kimchi.
[0411] The 16S rRNA sequence information of Lactobacillus plantarum IMB19 analyzed is as follows.
[0412] - Lactobacillus plantarum IMB19 16S rRNA (785 forward) (SEQ ID NO: 3)
[0413] AGCGCTGGGATGATGCTAGTGTTGGAGGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAAT TCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATACTATGCAAATCTAAGAGATTAGACGTTCCCTTCGGGGACATGGATACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCA
[0414]
[0415] - Lactobacillus plantarum IMB19 16S rRNA (907 reverse) (SEQ ID NO: 4)
[0416]
[0417] Example 3: Selection of Lactobacillus plantarum IMB19
[0418] To confirm the immunostimulatory effect of the isolated bacteria on immune cells, the effect of bacterial culture isolates on mouse spleen cells was tested, thus identifying bacteria with stimulatory effects on immune cells. Cytokine levels in the culture supernatant were measured after culturing total spleen cells with the isolated bacteria for 48 hours. The effects of the isolated bacteria on immune cells were evaluated using IFN-γ as a well-known inflammatory marker and IL-10 as an anti-inflammatory cytokine. Among all isolated bacteria, a novel *Lactobacillus plantarum* strain inducing negligible levels of IL-10 and very high levels of IFN-γ was selected and named *Lactobacillus plantarum* IMB19. Figure 1 Colony 1).
[0419] Example 4: Analysis of the microbiological and biochemical characteristics of Lactobacillus plantarum IMB19
[0420] The colonies of *Lactobacillus plantarum* are small, smooth, round, and translucent. Cryosection TEM confirmed that *Lactobacillus plantarum* has non-motile and rod-shaped microbial colonies. Figure 2 (See small figure A). The thick capsule layer of a single bacterium is clearly observed. When cultured on sheep blood agar, neither clear nor green areas are formed, thus confirming the corresponding strain as non-hemolytic or γ-hemolytic, like other lactobacilli. Figure 2 (See small figure B). Gelatinase activity was negative for Bacillus cereus ATCC 11778, used as a positive control, for up to 5 days. Figure 2 (See Figure C). Furthermore, the production of four biogenic amines by the strains was tested in specialized culture media (histamine, cadaverine, tyramine, and putrescine). *Lactobacillus plantarum* IMB19 was found not to produce biogenic amines, unlike *Escherichia coli* ATCC 25922 (Table 1).
[0421] [Table 1]
[0422] Bioamine activity of Lactobacillus plantarum IMB19 and Escherichia coli ATCC 25922
[0423]
[0424] As shown in Table 2 below, the results of the antibiotic susceptibility test confirmed that the bacteria showed susceptibility to most clinically relevant antibiotics except kanamycin, like most Lactobacillus species (Appl. Environ. Microbiol. 85, (2019)).
[0425] [Table 2]
[0426] Antibiotic resistance test of Lactobacillus plantarum IMB19
[0427]
[0428] *EFSA = European Food Safety Authority, Amp = Ampicillin, Ery = Erythromycin, Gen = Gentamicin, Tet = Tetracycline, Str = Streptomycin, Chl = Chloramphenicol, Cli = Clindamycin, Kan = Kanamycin, Van = Vancomycin, nr = Not required, QC = Quality Control.
[0429] Example 5: Analysis of the genetic characteristics of Lactobacillus plantarum IMB19
[0430] The identification of *Lactobacillus plantarum* was confirmed by sequence similarity comparison based on 16S rRNA sequencing. Furthermore, it was distinguished from other genetically closely related species such as *Lactobacillus pentosus* and *Lactobacillus paraplantarum* by PCR analysis of the recA gene (Appl. Environ. Microbiol. 67, 3450-3454 (2001)).
[0431] Analysis was performed based on DNA isolation, Pac-Bio & Illumina Hi-seq sequencing, and bioinformatics (Macrogen, South Korea).
[0432] Lactobacillus plantarum IMB19 was distinguished from other genetically closely related species by amplifying the recA gene using primers derived from the recA gene and comparing its bands. Since several Lactobacillus plantarum strains are known to share genome-wide similarities, phylogenetic analysis was performed based on the OrthoANI (Ortho-Nucleotide Index), and Lactobacillus plantarum IMB19 was identified as a unique strain. Figure 3 Based on the homology of the virulence gene sequence with four known strains, the presence of the putative virulence gene was confirmed using VirulenceFinder 2.0. Using a 90% nucleotide cutoff, no significant hits of the virulence gene were found. As can be seen from ResFinder (J. Clin. Microbiol. 52, 1501-1510 (2014)), the absence of antibiotic resistance genes in the whole genome of *Lactobacillus plantarum* IMB19 was confirmed.
[0433] As disclosed in the above embodiments, Lactobacillus plantarum IMB19 was discovered to be a novel strain, which has characteristics different from conventionally reported Lactobacillus plantarum strains, and was deposited at the Bioresource Center of the Korea Institute of Life Science and Technology on October 21, 2020, with accession number KCTC 14337BP.
[0434] Example 6: Immunostimulatory effect of Lactobacillus plantarum IMB19 on mouse T cells
[0435] The beneficial effects of several strains of *Lactobacillus plantarum* on host immunity and health are well known (Biomed.Res. Int. 2018, 9361614 (2018)), and the direct effect of *Lactobacillus plantarum* IMB19 of this invention on mouse immune cells has been demonstrated. The inventors predicted that the uptake of bacterial antigens by antigen-presenting cells (APCs) would enable alterations in activation status, thereby triggering other immune cells and thus modulating the immune system. Therefore, a co-culture system containing both APCs and CD4+ T cells (representing the innate and adaptive immune systems, respectively) was designed. CD11c+ APCs were exposed to bacteria for 20 hours (APC:bacteria = 1:100). These APCs were then co-cultured with naive CD4+ T cells under suboptimal external stimulation that did not shift the immunophenotype. To demonstrate T cell differentiation into Th1, Th2, Th17, or regulatory T cells (Tregs), other transcription factors, such as Tbet, GATA3, RORγ, and Foxp3, were analyzed. In the absence of specific external influences, compared with the other three strains, *Lactobacillus plantarum* IMB19 significantly induced the production of CD4+ RORγ+ Th17 cells. Figure 4 (See small figure A). The significant generation of other Th cell subtypes is uncertain and similar to other Lactobacillus plantarum strains ( Figure 4 (Small image B).
[0436] To verify the above results, Th17 cell production induced by *Lactobacillus plantarum* IMB19 was tested under conditions of minimal Th17 cell production. *Lactobacillus plantarum* IMB19 significantly increased the production of CD4+ RORγ+ Th17 cells, producing a significant amount of IL-17 (…). Figure 5 (Small image A).
[0437] On the other hand, *Lactobacillus plantarum* IMB19 does not induce significant amounts of Foxp3 under neutral conditions. Figure 5 (See Figure B). Therefore, based on the results confirming whether Lactobacillus plantarum IMB19 can produce Tregs from naive CD4+ T cells at sufficient concentrations of TGF-β, the production of Tregs was significantly inhibited with increasing TGF-β concentration.
[0438] Example 7: Confirmation of the in vivo effect of Lactobacillus plantarum IMB19 in promoting anti-tumor immune response
[0439] Lactobacillus plantarum strain IMB19 and various Lactobacillus strains (14 types) as controls were co-cultured with spleen cells to compare whether immune cells altered cytokine production. The results showed that, compared with other Lactobacillus strains, Lactobacillus plantarum strain IMB19 exhibited significantly higher IFN-γ levels and significantly lower IL-10 levels. Figure 6 (See small figure A). For reference, another strain of *Lactobacillus murineis* exhibited the highest ability to induce IL-10 and a low ability to produce IFN-γ (see small figure A). Figure 6 (Small image A).
[0440] Since CD8+ T cells are the primary anti-tumor effector cells, the ability of the two isolated strains to stimulate CD8+ T cells was confirmed. In the co-culture of bacterial-induced dendritic cells (DCs) and CD8+ T cells, IFN-γ levels increased upon treatment with *Lactobacillus plantarum* IMB19, and were significantly increased, particularly compared to treatment with *Lactobacillus murineis*. Figure 6 (See small figure B). After co-culturing with spleen and mesenteric lymph node antigen-presenting cells, CD8+ T cell activation was altered in a bacterial concentration-dependent manner. Figure 7 small picture A and Figure 7 (Small image B).
[0441] Lactobacillus plantarum IMB19 does not directly stimulate CD8+ T cells in the absence of dendritic cells. In the presence of antigen gp-100, CD8+ T cells carrying TCRs against the mouse melanoma-specific antigen Pmel-1 are similarly activated. Figure 7 (See small figure C). Besides dendritic cells (DCs), macrophages are known APCs that play important roles in tumor growth and suppression; therefore, the effect of *Lactobacillus plantarum* IMB19 on CD8+ T cell stimulation via CD11b+ F4 / 80+ peritoneal macrophages was examined. Similar to dendritic cells, *Lactobacillus plantarum* IMB19 significantly increased the proportion of IFN-γ+ CD8+ T cells during co-culture of macrophages and CD8+ T cells (…). Figure 6 (small image C).
[0442] CD4+ Foxp3+ regulatory T cells (Tregs) accumulate in tumors and increase tumor progression by inhibiting the effector functions of CD8+ T cells and other immune cells. Furthermore, several bacteria that promote Treg production have been reported (Nature 453, 620-625 (2008); Sci. Immunol. 3, (2018)). Therefore, the inventors have demonstrated whether *Lactobacillus plantarum* IMB19 affects Treg induction during co-culture of CD11c+ DCs and CD4+ T cells. *Lactobacillus plantarum* IMB19 significantly inhibited Treg production under strong Treg-shifted culture conditions in the presence of TGF-β (…). Figure 6 (See small figure D). This effect persisted even at lower TGF-β levels, and no Treg production was observed under any test conditions. Figure 8 (See small figure A). On the other hand, the level of interleukin-17A (IL-17A) increases ( Figure 8 Figure B shows the production of T-helper-17 cells (Th17). Interleukin-6 (IL-6) is essential for Th17 production and inhibits Treg production in the presence of TGF-β (Eur. J. Immunol. 40, 1830-1835 (2010)). Therefore, IL-6-deficient DCs produce Tregs during co-culture with CD4+ T cells. Thus, under Treg-biased culture conditions, IL-6 production by DCs induced by Lactobacillus plantarum IMB19 inhibits Treg production.
[0443] To test whether CD8+ T cells activated by *Lactobacillus plantarum* IMB19 are functionally cytotoxic, an acute listeriosis infection model expressing the OVA antigen (LM-OVA) was used to test cytotoxicity. Figure 6 (See small figure E). Mice infected with LM-OVA and fed with Lactobacillus plantarum IMB19 showed a significant increase in the lysis of target cells of CFSE loaded with OVA pulses in vivo. Figure 6 (See Figure F). Furthermore, the effects of *Lactobacillus plantarum* IMB19 on subcutaneously inoculated B16.F10 melanoma-infected SPF (specific pathogen-free) and GF (germ-free) mice were evaluated. Figure 6 (See small figure G). Compared to *Lactobacillus murineis*, *Lactobacillus plantarum* IMB19 showed significant inhibition of melanoma growth in both SPF and GF mice. Figure 6 small image H and Figure 6(See Figure I). To evaluate whether *Lactobacillus plantarum* IMB19 induces any dysbiosis leading to antitumor effects, 16S ribosomal RNA was sequenced from fetal samples of tumor-bearing animals fed with *Lactobacillus plantarum* IMB19. However, compared to the PBS control, there was no significant change in microbial diversity in the feces of mice fed with *Lactobacillus plantarum* IMB19 (…). Figure 9 A- Figure 9 (C) This means that the antitumor immune regulation mediated by *Lactobacillus plantarum* IMB19 corresponds to the specific action of *Lactobacillus plantarum* IMB19 and is not a result of dysbiosis. Therefore, the data in this embodiment indicate that *Lactobacillus plantarum* IMB19 is a positive regulator of cytotoxic T cell-mediated antitumor immune responses in vivo.
[0444] Example 8: Analysis of the chemical characteristics of crude polysaccharide fractions derived from Lactobacillus plantarum IMB19
[0445] Based on the analysis results using transmission electron microscopy (TEM), it was confirmed that the cells of *Lactobacillus plantarum* IMB19 were surrounded by a capsule material containing a carbohydrate composition consisting of rhamnose, galactose, glucose, glucosamine, and small amounts of glycerol and ribitol. Figure 10 and Figure 11 (See Figure A). These two polyols are commonly associated with the presence of teichoic acid, which is interconnected via phosphodiester linkages (Tomita, Tanaka, and Okada, 2017). Detection of these polyols is typically very difficult because methanol decomposition does not completely cleave the phosphodiester linkages. Therefore, GC-MS analysis was repeated by dephosphorylating the sample with an aqueous HF solution prior to methanol decomposition and acetylation, and the presence of teichoic acid was confirmed based on the increasing amounts of both polyols. For monosaccharides, rhamnose has an absolute L-configuration, while glucose and galactose have D-configurations (…). Figure 12 On the other hand, for glucosamine, the D configuration is assumed based on the unique existence of stereoisomers.
[0446] Example 9: Purification of crude polysaccharide
[0447] Chemical analysis of the carbohydrate components indicated that CPS could be a mixture of polymers. Therefore, the six fractions obtained by purifying CPS using ion-exchange chromatography are denoted as CPS-X, where "X" indicates the concentration of the eluent used. The yields obtained by purification are as follows: CPS-10 11%, CPS-100 13%, CPS-200 9.0%, CPS-400 51%, CPS-700 7.0%, and CPS-1000 7.9%. 1 1H NMR analysis compared the spectral distribution of each fraction with that of the original mixture (CPS). Figure 13 ).
[0448] Specifically, the individual classifications are as follows ( Figure 13 ).
[0449] CPS-10 ( Figure 13 (Figure b): CPS-10 exhibits a rather heterogeneous spectrum. The anodic region of CPS-10 includes two main strong signals at 4.2 ppm and 1.3 ppm, which is consistent with materials that are different from carbohydrates.
[0450] CPS-100 ( Figure 13 (Inset c): The anomeric region of CPS-100 (5.6 ppm–4.5 ppm) includes nine major signals, with a doublet at 5.5 ppm, indicating that the residues are in the α configuration. 3 J H1,H2 =3.4 Hz) and phosphorylation ( 3 J H1,P =7.0 Hz) Figure 14 Furthermore, strong signals for acetyl groups (methyl groups at 2.06 ppm) and several methyl groups including deoxygenated residues (1.3 ppm) were observed, consistent with the presence of N-acetylglucosamine and rhamnose units, respectively.
[0451] CPS-200 ( Figure 13 (Small figure d): CPS-200 appears as a mixture with CPS-100 and CPS-400, showing four fairly wide signals in the anodic region, and strong methyl signals at 1.6 ppm (a value inconsistent with methyl in rhamnose) and in the crowded methanol region (4.4 ppm–3.2 ppm).
[0452] The integral shows an anoproton to methanol proton ratio of 1.0:12, and the typically expected ratio is 1:6 or less, indicating that CPS-400 does not have a typical polysaccharide structure, and that the increase in the ratio is due to the presence of ribitol and glycerol units, as confirmed by chemical analysis. Figure 15 In addition, glucose is the most abundant monosaccharide, followed by two smaller amounts of glucosamine (GlcN) and muramic acid (MurA), which are characteristic of peptidoglycans.
[0453] This observation indicates that CPS-400 is teichoic acid (TA).
[0454] CPS-700 and CPS-1000 ( Figure 13 small image f and Figure 13 (Small figure g): The anodic region contains only some of the signals found in CPS-400, and the ratio of anodic protons to methanol protons in both fractions is atypical. Signals from non-carbohydrate materials were also observed.
[0455] CPS-10, CPS-700 and CPS-1000 are not abundant in CPS, so only a small amount of them are obtained.
[0456] Example 10: NMR Analysis of CPS-100
[0457] By analyzing the entire dataset recorded at 310 K 1 H- 1 H homonuclear (COSY, TOCSY, NOESY) and 1 H- 13 The structure of the capsular polysaccharide was determined by C heteronuclear (HSQC, HMBC, HSQC-TOCSY) 2D NMR spectroscopy (Table 3).
[0458] [Table 3]
[0459] The protons of the repeating unit of CPS-100 ( 1 H, static) NMR chemical shift and carbon ( 13 C (italicized) NMR chemical shift
[0460]
[0461] * C-3 cells where C and E overlap, and whose exact chemical shift cannot be definitively determined.
[0462] **C-5 with overlapping C, E, G, and H atoms, and whose exact chemical shift cannot be definitively determined.
[0463] Temperature from 297 K ( Figure 13 The small graph (c) rises to 310 K ( Figure 14 This reduces the overlap between the three anodic signals at approximately 5.15 ppm and simplifies the NMR characteristics of the associated residues.
[0464] HSQC spectrum ( Figure 14 ) displayed 1 The nine main anodic densities at H 5.6-4.5 are derived from... Figure 14 The small figure a and the capital letters AI in Table 3 indicate that the corresponding protons are all present in similar proportions. NMR analysis began at H-1 (5.51 ppm) in A, showing three correlations in the TOCSY spectrum, similar to 3.85 ppm in the COSY spectrum. Figure 16 Therefore, this density was assigned to H-2, and H-3 (3.91 ppm) and H-4 (4.04 ppm) were assigned in a similar manner. Since there was no further correlation with H-1, A was identified as the galactose unit. Due to the strong H-4 / H-5 correlation, H-5 was identified in the NOESY spectrum (…). Figure 17), and two H-6s were identified through the corresponding COZY-related identification. Figure 16 and Figure 17 ).
[0465] HSQC and HSQC-TOCSY spectra ( Figure 18 In small figure a), all carbon chemical shifts of A are defined based on the high chemical shift of C-6 (67.1 ppm) (Table 3), where A is an α-galactose unit linked to O-6. Since the correlation of the TOCSY spectrum of H-1 (5.12 ppm) derived from D has the same pattern as that of A, D is galactose, based on... 3 J H1,H2 The (3.9 Hz) value indicates an α configuration, and the chemical shifts of H-6 / C-6 (4.04 ppm–4.02 ppm / 65.6 ppm) imply phosphorylation at this position, consistent with data from the literature (Sechenkova et al., 2004). Therefore, D is 6P-α-Gal, and based on the high field values of all other carbon chemical shifts, it is determined that D no longer branches.
[0466] For B, H-1 (5.24 ppm) showed two strongest TOCSY correlations with H-2 (4.25 ppm), consistent with the COZY density. Figure 16 As a result of reading TOCSY from this second proton ( Figure 16 The presence of all other protons containing the methyl unit at 1.28 ppm confirmed the overall diagnostic of the rhamnose residue pattern. Therefore, B is rhamnose in the α-configuration at the anodic center, based on the similarity of its C-5 value (approximately 70.5 ppm) to the reference glycosides (69.4 ppm or 73.6 ppm for α- or β-methyl glycosides, Bock & Pedersen, 1983), and is 3-substituted as defined by the glycosylation transitions experienced at the corresponding carbons. The TOCSY patterns of residues C, E, G, and H (H-1 at 5.14 ppm, 5.10 ppm, 4.97 ppm, and 4.88 ppm, respectively) are similar to B, thus they are α-rhamnose units, and the low field value of C-2 (77.8 ppm–79.6 ppm) compared to the reference value (71.0 ppm, Bock & Pedersen, 1983) implies substitution at O-2.
[0467] For F, H-1 (5.01 ppm), there are four TOCSY-related ( Figure 16This is attributed to H-2 to H-5 in the COSY spectrum and is a pattern of glucose conformation residues. HSQC-TOCSY analysis of H-5 confirmed a correlation with the density at 69.5 ppm, attributed to C-6, and in turn correlated with H-6 (4.14 ppm and 3.96 ppm). Therefore, F was determined to be N-acetylglucosamine based on the C-2 (54.9 ppm) and H-2 (3.93 ppm) values and the substitution at C-6 (69.4 ppm). The α-configuration was inferred from the shape of the anolyte signal (broad singlet) and the C-3 value (71.8 ppm), which was very similar to the reference α-glycoside (72.0 ppm, Bock & Pedersen, 1983). Finally, H-1 (4.50 ppm) of I has a TOCSY pattern representing all protons of the unit. Therefore, based on 13 C chemical shift, I was determined to be glucose substituted at C-3 (82.8 ppm) and based on 3 J H1,H2 The value (7.9 Hz) is in β-configuration.
[0468] By analyzing the HMBC spectrum ( Figure 5 Small image b) and NOESY spectrum ( Figure 4 The sequence between residues is derived. First, the correlation between the HMBC linked by H-1 of B and C-3 of I and the corresponding density is represented as B1I3 ( Figure 18 (See small figure b). Other correlations were found in the same manner, such as C1E2, D1B3, F1G2, H1A6, and I1F6. Furthermore, the H-1 of E and the H-1 of G showed long-range correlations with carbon at approximately 79 ppm (a value similar to the C-2 of C and H). The precise allocation of these densities to E1H2 and G1C2 was inferred by analyzing the NOESY spectra correlated with the H-1 of E and the H-2 of H, as well as with the H-1 of G and the H-2 of C. Figure 17 These properties were confirmed by observing the detailed inverse correlations in H-2 proton amplification of different rhamnose units. Figure 19 ).
[0469] Finally, information regarding the phosphorylation of A and D via phosphodiester linkages at O-1 and O-6, respectively, explains why no HMBC linkages occur between the H-1 of A and the C-6 of D, or between the H-6 of D and the C-1 of A, or why these protons show no NOE correlation between residues. In fact, HMBC spectroscopy cannot detect any correlation between the two units because the number of linkages (5) between the H-1 (or C-1) of A and the C-6 (or H-6) of D exceeds the sequence limit (3 linkages). Similarly, the density of the phosphate moiety between A and D keeps the protons of these units very far apart to provide detectable NOE action. Therefore, the repeating unit structure of CPS-100 is non-sugar, as... Figure 20 As reported in China.
[0470] In addition, a small number of NMR signals were studied to understand their characteristics. In the HSQC spectrum ( Figure 14 In ), the carbon chemical shifts of indicative densities such as Galα and Galβ (respectively...) 1 H / 13 C 5.26 ppm / 93.5 ppm and 4.57 ppm / 97.8 ppm) show α or β residues in their free reduced form. The TOCSY spectrum of H-1 ( Figure 16 The results show a typical pattern for sugars with a galactose conformation (i.e., for Galα, the third density almost overlaps with the COZY density). These findings can be explained by considering that the procedures used to separate CPS include sonication and trichloroacetic acid treatment, both of which are able to induce some cleavage of phosphodiester linkages, particularly the anomeric phosphate of galactose A, due to the extreme instability of phosphodiester linkages. Therefore, a small signal adjacent to a strong signal is expected ( Figure 14 (Indicated by "*") belongs to the first repeating residue and is linked to galactose in its free reduced form. However, its low intensity and dense methanol region hinder accurate identification of its properties. Finally, in the HSQC spectrum ( Figure 14 In small figure a), the sample has an average degree of polymerization of 4 and an average MW of about 6 kDa (MW of repeating units is 1500 Da) on the integral of anodic density, where 11 kDa (calculated based on HPSEC) appears to be a slightly high estimate. Figure 21 ).
[0471] Example 11: NMR Analysis of CPS-400
[0472] The structural features of CPS-400 are analyzed in a manner similar to that described in the above embodiments (Table 4).
[0473] [Table 4]
[0474]
[0475] First, HSQC spectrum ( Figure 22 small image a and Figure 22 The anodic region in small figure b) shows several residues, including those appearing at monosaccharide residues. 1 The signal at H is 5.3 ppm-5.1 ppm, while... 1 H / 13 The signal at C 5.39 ppm / 75.5 ppm is not anomaly, but rather represents the C-2 of the glycerol unit (Gro) of A, shifted to a lower field due to acylation. The substituent at O-2 is alanine (Ala), which is derived from... 1 H / 13 The methyl group at C 1.64 / 16.5 ppm and the Hα / Cα group at 4.30 ppm / 50.2 ppm were identified. Furthermore, the H-1 / C-1 and H-3 / C-3 of A are equivalent and based on the corresponding HSQC-TOCSY (…). Figure 22 Small picture A) and TOCSY ( Figure 22 The small figure (G) is related to the identification at 4.11 ppm / 65.0 ppm.
[0476] Finally, the C-1 (or C-3) values indicated the identification of a second 1,3-bisphosphorylated Gro unit (B) and a 1,5-bisphosphorylated ribitol unit (Rbo, C) in the HSQC analysis, which can be referenced to Gerlach et al., 2018, who indicated that A was phosphorylated at both ends, as in the case of Gro-type teichoic acid, and the last residue suggested the presence of another teichoic acid based on the ribitol-phosphate backbone. For monosaccharide units, the analysis focused on the strongest signals (D, E, F', and F), which were identified as α-glucose units based on magnetization in the anodic signal of the TOCSY spectrum up to the effective propagation of H-6. 13 Due to the similarity of C chemical shifts, these Glc units are no longer substituted (Bock & Pedersen, 1983).
[0477] The positions of these units were inferred through HMBC spectral analysis and comparison with reference data. Indeed, E is connected to the O-2 junction of the Gro unit (H) (Shashkov, Potekina, Senchenkova, and Kudryashova, 2009), while F' is connected to the O-4 junction of the Rbo unit (I) (Streshinskaya et al., 2011). For D, H-1 shows a long-range correlation with carbon at 78.3 ppm (…). Figure 18 (See small figure b), where the proton (4.30 ppm) is linked to "CH2" at 69.9 ppm in the HSQC-TOCSY spectrum. Figure 23This new unit is denoted as G, and will be... 1 H / 13 Densities at C 4.30 ppm / 78.3 ppm and 4.14 ppm / 66.9 ppm were assigned to G4 and G5 ( Figure 18 small image c and Figure 23 G was identified as ribitol, and other signals were detected by HSQC-TOCSY spectral analysis. In fact, in 1 H / 13 The "CH2" density at C 4.16 ppm / 67.7 ppm has three correlations with the signal indicating G4, and this density is denoted as G1. Furthermore, C-1 (67.7 ppm) of G represents the unglycosylated but phosphorylated carbon at an adjacent position, as reported for I. This information leads to the assignment of the remaining two HSQC-TOCSY correlations to C-2 (70.5 ppm) and C-3 (80.6 ppm), and conversely, the corresponding H-2 (4.15 ppm) and H-3 (3.97 ppm) are identified in the HSQC spectrum. Figure 18 , Figure 23 (and Table 4). Therefore, G is Rbo glycosylated at O-3 and O-4, and the two units F and D ( Figure 22 Connect HMBC in small figure b to it.
[0478] This type of substitution has been identified in other *Lactobacillus plantarum* strains, but their NMR data reported phosphate-free Rbo units, thus these chemical shifts cannot be compared with the data of this invention (Tomita et al., 2017). However, the results of this invention are similar to those of *Bifidobacterium* teichoic acid (Valueva et al., 2013), indicating a reverse substitution pattern of ribitol with glucose units linked at C-2 and C-3 (Valueva et al., 2013). Interestingly, the NMR data of the dephosphorylated form reported by Valueva et al. (2013) are consistent with the NMR data of 3,4-diglusylated ribitol reported by Tomita et al. (2009). Therefore, the substitution pattern of the ribitol unit (2,3 or 3,4) has not been definitively defined. Thus, the NMR data of this invention indicate that CPS-400 is a mixture of Gro-type and Rbo-type teichoic acids, each showing the presence of several substituents in a non-stoichiometric manner. For Gro-type TA, the non-stoichiometric substituents are alanine and α-glucose. For Rbo-type TA, α-glucose does not appear at either O3 or O4 of ribitol, only at O4, or at any position. Attempts were made to separate the two TAs by size exclusion chromatography, but CPS-400 showed a symmetrical peak of approximately 45 kDa. Figure 21 ), and cannot be further separated.
[0479] Example 12: Immunostimulatory activity of CPS-100 and CPS-400
[0480] The activity of CPS-100 and CPS-400 in the immune response was confirmed.
[0481] The role of CPS in the immune system was demonstrated using spleen cells in which all immune cells were mixed at physiological ratios. Endpoint analysis was performed by testing different cytokines via ELISA. Cytokines are a group of secreted peptides / glycoproteins involved in cell signaling, mediating and regulating inflammatory or tolerative immune responses in vivo. Therefore, a shift in cytokines in the immune cell pool upon exposure to CPS implies similar effects in vivo. To demonstrate the immune responses generated by CPS-100 and CPS-400, interferon-γ (IFN-γ) was used as an inflammatory marker and interleukin-10 (IL-10) as a regulatory cytokine. The results indicated that CPS-100 is immunostimulatory, as evidenced by high IFN-γ production and negligible IL-10 production. Figure 24 small image a and Figure 24 (See small figure b). On the other hand, no level of IFN-γ was detected in the CPS-400 (TA fraction). Figure 24 (See Figure a). Under similar conditions, other cytokines were evaluated, including TNF-α (tumor necrosis factor-α), IL-6 (interleukin-6), IL-12 (interleukin-12), IL-17 (interleukin-17), and IL1-β (interleukin-1β).
[0482] CPS-100-stimulated cells produce very high levels of TNF-α, IL-6, and IL-12. Figure 24 small image C to Figure 24 (Figure E), while IL-17 and IL-1β were not detected. On the other hand, CPS-400 did not show a significant increase in any measured cytokines (Figure E). Figure 24 small image c and Figure 24 (See Figure e). Since IFN-γ is a major immunostimulatory marker produced by various types of immune cells, to confirm the specificity of the CPS immunostimulatory response, it was evaluated whether IFN-γ production depended on the concentration of CPS-100. During 48 hours of IFN-γ induction, the half-maximal effective concentration (EC50) of CPS-100 was 3.16 μM (…). Figure 24 The small figure (f) shows that CPS-100 can be used as an effective immunostimulant.
[0483] Therefore, CPS-100 exhibits similar immunostimulatory properties to Lactobacillus plantarum IMB19 strain, which means that the effective molecule that exhibits the immunostimulatory activity of Lactobacillus plantarum IMB19 strain is CPS-100.
[0484] Example 13: Improvement of CD8+ T cell function and antitumor immune effects of Lactobacillus plantarum IMB19 and CPS
[0485] The study evaluated whether the activity of CPS as an in vitro immunostimulant could lead to in vivo tumor suppression activity. It was confirmed that the growth of subcutaneous melanoma was significantly reduced in both the oral administration of Lactobacillus plantarum IMB19 and the intraperitoneal administration of CPS treatment groups. Figure 25 small picture A and Figure 25 (See small figure B). In both groups, delayed tumor growth was associated with CD8+ T cell infiltration. Figure 25 (See small figure C). The increased IFN-γ production and frequency achieved by tumor-infiltrating CD8+ T cells implies a significant increase in the cytotoxic activity of CD8+ T cells due to the above-mentioned administration. Figure 25 small picture E and Figure 25 (See small figure F). Intratumoral CD4+ T cells also showed upregulation of IFN-γ production in both treatment groups. Figure 25 small image G and Figure 25 (See small figure H). Conversely, there was no difference in intratumoral Treg populations compared to the PBS administration group ( Figure 26 small picture A and Figure 26 (Small Figure B). Oral administration of Lactobacillus plantarum IMB19 regulates tumor growth in EMT-6 breast cancer ( Figure 27 Therefore, these data indicate that CPS and Lactobacillus plantarum IMB19 enhance antitumor immune activity by inhibiting cancer growth.
[0486] Example 14: Increased intratumoral macrophage infiltration due to CPS
[0487] CPS increased macrophage infiltration in tumors. To identify specific APC types that regulate CD8+ T-cell responses, intraperitoneal administration of CPS was performed, followed by inoculation of B16.F10 melanoma cells, and APC infiltration in early-stage tumors was assessed. Compared to CD11c+ DCs, CPS primarily increased the frequency of CD11c+CD11b+ macrophages in tumors ( Figure 28 (See small figure A). Flow cytometry confirmed that the number of macrophages was very high in mice treated with CPS ( Figure 28 (See Figure A). Activation markers for CD11c+CD11b+ macrophages and CD11c+ dendritic cells were identified under the same conditions. Surprisingly, the activation status of CPS-treated dendritic cells did not show a significant difference compared to the control group (…). Figure 28 (See Figure C). However, macrophages were more strongly activated and showed higher expression of CD11b, MHC I, MHC II, CD86, and CD40. Figure 28 (See small figure B). To confirm the activation of the systemic adaptive immune system in the same mice, CD69, a marker of early activation of CD8+ T cells, was identified in draining lymph nodes. Compared with the control group, CD69 was significantly and substantially upregulated due to CPS administration (see small figure B). Figure 28 (See small figure D). These data indicate that CPS plays an important role in macrophage activation and can limit tumor growth.
[0488] Example 15: Macrophages differentiate into inflammatory macrophages via CPS and macrophages reprogrammed from the M2 phenotype to the M1 phenotype.
[0489] To characterize the effects of CPS on macrophages, phenotypic changes in macrophages upon exposure to CPS were demonstrated. Peritoneal CD11b+ F4 / 80+ macrophages exhibited an activated phenotype upon CPS treatment, and compared to macrophages treated with LPS or Pam3CSK4, macrophages treated with CPS showed significant upregulation of MHC I, MHC II, CD68, iNOS2, and CD40. Figure 28 The small figure (E) thus indicates the M1 phenotype or inflammatory phenotype of macrophages. Specifically, similar to Pam3CSK4, TLR2 was upregulated after CPS treatment, suggesting that CPS can be a TLR2 ligand. However, in contrast to in vivo experiments, the expression of CD80 and CD86 remained unchanged. Figure 28 (Small image E).
[0490] Alternatively, activated macrophages or M2 phenotype macrophages significantly promoted immunosuppression and enhanced tumor growth (On Oncol. 28, xii18-xii32 (2017)) (Front Oncol. 9, 421 (2019)). Therefore, these results suggest that CPS in tumors can reprogram M2 macrophages to the M1 phenotype. Indeed, the number of IL-4-induced M2 phenotype peritoneal macrophages was significantly increased with CPS compared to when LPS and Pam3CSK4 were used ( Figure 28 (See Figure F). Furthermore, the inflammatory macrophage marker iNOS2 was significantly upregulated independently of MHC I, MHC II, CD40, and CD68. Figure 5 (See small figure F). These data indicate that CPS treatment generates inflammatory macrophages and reprograms immunosuppressive macrophages to an immunostimulatory phenotype.
[0491] Although specific embodiments of the invention have been disclosed in detail above, it will be apparent to those skilled in the art that the descriptions are merely preferred exemplary embodiments and should not be construed as limiting the scope of the invention. Therefore, the essential scope of the invention should be defined by the appended claims and their equivalents.
[0492] Login ID
[0493] Name of depository: Korea Institute of Biotechnology
[0494] Login ID: KCTC14337BP
[0495] Preserved specimen: Lactobacillus plantarum IMB19 strain
[0496] Date of preservation: October 21, 2020
[0497] Industrial applicability
[0498] According to the present invention, the novel *Lactobacillus plantarum* strain IMB19 and the polysaccharides derived from said strain exhibit a strong ability to stimulate CD8+ T-cell activity and excellent Treg cell inhibitory activity, and stimulate and enhance anti-tumor immune responses through various mechanisms such as increased macrophage infiltration within tumors and macrophage differentiation / reprogramming into an inflammatory (M1) phenotype via CPS. Therefore, the strains and polysaccharides derived from the strains according to the present invention can be used for immunomodulation in subjects, particularly for immune enhancement, and can induce and improve anti-tumor immune responses, thereby inhibiting tumor growth. The novel strains and polysaccharides derived from the strains according to the present invention can be used for the prevention, improvement, or treatment of various immune diseases, such as tumors, infectious diseases, and various immune diseases caused by or symptom of immune dysfunction.
[0499] Sequence List Free Text
[0500] Electronic documents are attached.
[0501] PCT
[0502] (Original electronic format)
[0503]
Claims
1. A polysaccharide comprising the following formula I: -[-D-B-I-F-G-C-E-H-A-] n - [Formula I] In equation I, A and D are galactose. B, C, E, G, and H are rhamnose. F is N-acetylglucosamine. I is glucose, and n is an integer of 1 or greater.
2. A capsular polysaccharide derived from the Lactobacillus plantarum strain IMB19, said strain having accession number KCTC 14337BP, wherein the capsular polysaccharide comprises a polysaccharide represented by formula I: -[-D-B-I-F-G-C-E-H-A-] n - [Formula I] In equation I, A and D are galactose. B, C, E, G, and H are rhamnose. F is N-acetylglucosamine. I is glucose, and n is an integer of 1 or greater.
3. A composition for immunomodulation comprising the polysaccharide according to claim 1 or the capsular polysaccharide according to claim 2 as an active ingredient.
4. A pharmaceutical composition for treating tumors, comprising the polysaccharide according to claim 1 or the capsular polysaccharide according to claim 2 as an active ingredient, wherein the tumor is melanoma or breast cancer.
5. A method for generating inflammatory T cells, comprising: (a) Initiating antigen-presenting cells with the polysaccharide according to claim 1 or the capsular polysaccharide according to claim 2; as well as (b) Co-culture the antigen-presenting cells induced by the above method with T cells. The inflammatory T cells mentioned therein are CD4+ RORγ+ Th17 cells and / or CD8+ T cells.
6. The method of claim 5, wherein the antigen-presenting cells are selected from the group consisting of macrophages, B cells, dendritic cells (DCs), and Langerhans cells.
7. A method for generating M1 phenotype macrophages, comprising: Macrophages were differentiated into M1 phenotype macrophages by treating them with the polysaccharide according to claim 1 or the capsular polysaccharide according to claim 2. as well as The differentiated M1 phenotype macrophages were obtained.
